Drivers of epithelial-mesenchymal transition in chronic obstructive pulmonary disease by Nowrin, K
Drivers of epithelial-mesenchymal 
transition in chronic obstructive 
pulmonary disease 
By 
Kaosia Nowrin 
Submitted in fulfilment of the requirements for the Degree of Master of 
Pharmacy by Research, School of Medicine, University of Tasmania, August, 
2015  
ii 
Declaration 
I hereby declare that this thesis contains no material which has been accepted 
for the award of any other degree or diploma in any university and, to the best 
of my knowledge, contains no material previously published or written by any 
other person unless due reference is made in the text of this thesis. 
Kaosia Nowrin 
University of Tasmania, Hobart 
29
th
 August, 2015  
iii 
Acknowledgements 
The author wishes to thank several people. I would like to express the deepest 
appreciation for my supervisor, Professor E Haydn Walters, who has shown the 
attitude and inspiration of a genius, he continually and persuasively conveyed a 
spirit of adventure in regard to medical research and knowledge. Without his 
supervision and constant help this thesis would not have been possible. I would 
also like to thank my other supervisors, Dr Rahul Patel and Dr Sukhwinder 
Singh Sohal for their guidance and support in completion of this project. I 
would like to show my appreciation to Mr Steve Weston, research laboratory 
manager, who taught me the necessary technical skills, and laboratory training 
required throughout the project, as well as his immense support to complete the 
thesis. Also, a big thanks to the participants who were kind enough to give us 
their samples; without their support, this study would not have been possible. In 
addition, thank you to the other members of the Respiratory Research Group, 
especially my friends Tricia Spafford, Mariya Ahmed and Pawan Grewal, who 
have given me tremendous support and encouragement throughout the year. 
Moreover, I would like to thank Dr Jo-Maree Courtney for her generous 
contribution to the scientific figures in this thesis. Last but not least, I would 
like to thank my parents, my brothers for whom I dedicate my respect and love 
of knowledge, and my father for his beautiful advice “Knowledge is power”, 
which has always been a catalyst for me to pursue knowledge.   
iv 
Table of contents 
Contents 
1.1 Chronic obstructive pulmonary disease......................................................................1 
1.1a Epidemiology and global impact of COPD..............................................................1 
1.1b Clinical physiology …………………………..........................................................2 
1.1c Risk factors associated with COPD..........................................................................3 
1.2 Pathology of COPD ................. ..... ...........................................................................5 
1.2a Background to pathology  ............... ............................... ........................................5 
1.2b Airway component  ........ .........................................................................................7 
Central/large airways……………………............................…………………….7 
Small airways……………………………………………............................……8 
Lung parenchymal component……………............................…………………..8 
1.3 Epithelial mesenchymal transition (EMT) in COPD..................................................9 
1.3a CRE Breathe Well group work……………………………………………………..9 
1.3b Other groups’ work ........................... .......................................................................9 
1.4 Definition of EMT................................................................................... ...................11 
1.4a What is EMT..............................................................................................................11 
1.4b Potential EMT drivers in COPD...............................................................................11 
1.5 Transforming growth factor beta ................................................................................12 
1.5a Smad as transcription factor of TGFβ signaling  ......................................................12 
1.5b Alternative (non-smad) pathways of TGFβ signaling................................................12 
1.6 Other potentially primary transcription factor families ..............................................14 
1.6a Snail1, Snail2 (slug), Twist in EMT .........................................................................14 
1.7 Wnt pathway in EMT .................................................................................................15 
1.7a Role of Wnt and β-catenin.........................................................................................15 
1.8 Other pathways implicated in EMT.............................................................................16 
1.8a Hedgehog pathways  .................................................................................................16 
1.8b Integrin-linked kinase pathway .................................................................................16 
1.8c uPAR pathway ...........................................................................................................16 
1.9 Evidence of EMT drivers in human airways ...............................................................17 
1.9a Vessel-associated TGFβ activity in COPD smokers .................................................17 
1.10 Aim………………………………………………………………….........................19 
1.11 Rationale of study…………………………………………………………………...19  
2.1 Subjects and study design……………………………………………..………………20 
2.2 Statistics……………………………………………………………………………….21 
2.3 Bronchoscopy ……………………………………………………….………….……..21 
2.4 Processing of biopsies………………………………………………..……………..….21 
2.5 Sectioning of paraffin-embedded tissue blocks………………………………………..24 
2.6 Haematoxylin ………………………………………………………………………….26 
2.7 Immunostaining………………………………………………………………………...27 
2.8 Specimen preparation and heat induced antigen retrieval…………………….………..30 
2.9 Autoclave using Russell Hobbs Pressure Cooker……………………………………...30 
2.10 Dako Pretreatment (PT) link………………………………………………………….32 
2.11 Immunostaining protocol……………………………………………………………..33 
2.12 Controls……………………………………………………………………………….35 
2.13 Histological and immunohistochemical analysis……………………………………..36 
v 
3.1 Subjects demographics……………………………………………………………….39 
3.2 Cross-sectional study…………………………………………………………………41 
3.3 Epithelial cells ………………………………………………………………..………45 
3.4 Basal epithelial cells…………………………………………………....……………..47 
3.5 Rbm cells ………………………………………………………………………..……48 
3.6 Rbm vessels…………………………………………………………………………...49 
3.7 LP vessels…………………………………………………………………………..…51 
3.8 Inhaled corticosteroid effects…………………………………………………………53 
4.1 General overview………………………………………………………………..........55 
4.2 Epithelial layer………………………………………………………………………...55 
4.3 Sub-epithelial layer……………………………………………………………………58 
4.4 Future direction……………………………………………………………………….60 
4.5 Summary………………………………………………………………………………60 
 References………………………………………………………………………..61 
 Appendix…………………………………………………………………………72 
vi 
List of figures 
Figure 1.1: US cigarette use vs lung cancer deaths…………………………………….2 
Figure 1.2: Respiratory tree……………………………………………………………..3 
Figure 1.3: The link between smoking and pulmonary pathology……………………...4 
Figure 1.4: Epithelia-mesenchymal transition process………………………………….7 
Figure 1.5: The major potential drivers of EMT………………………………………..13 
Figure 1.6: Smad and non-smad pathways……………………………………………...14 
Figure 2.1: Automated processor Leica ASP200S……………………………………...22 
Figure 2.2: RA Lamb embedding centre………………………………………………...23 
Figure 2.3: Leica RM2255 Microtome…………………………………………………..25 
Figure 2.4: Labelled polymer horseradish peroxidase system…………………………..29 
Figure 2.5: Russell Hobbs Pressure Cooker……………………………………………..31 
Figure 2.6: DAKO PT link……………………………………………………………….32 
Figure 2.7: DAKO Autostainer plus……………………………………………………...33 
Figure 2.8: DAKO Coverslipper………………………………………………………….35 
Figure 2.9: Biopsy image analysis equipment……………………………………………36 
Figure 2.10: Showing two biopsy sections fixed on slide………………………………...37 
Figure 2.11: Showing a biopsy image under the microscope……………………………..38 
Figure 3.1: Microphotograph from subjects……………………………………………….42 
Figure 3.2: Variability in epithelium thickness……………………………………………43 
Figure 3.3: Variability in blood vessels……………………………………………………44 
Figure 3.4: Epithelial cells graph…………………………………………………………..46 
Figure 3.5: Basal epithelial cells graph…………………………………………………….47 
Figure 3.6: Rbm cells graph………………………………………………………………..48 
Figure 3.7: Rbm vessels graph……………………………………………………………..50 
Figure 3.8: LP vessels graph……………………………………………………………….52 
Figure 3.9: Rbm & LP vessels for longitudinal study……………………………………...54 
Figure 4.1: The TGFβ signaling…………………………………………………………….56 
vii 
 
List of Tables 
Table 2.1: Haematoxylin Reagents……………………………………………………..26 
Table 2.2: Immunostaining reagents……………………………………………………27 
Table 2.3: Buffer solution reagents……………………………………………………..28 
Table 2.4: Primary antibody…………………………………………………………….28 
Table 2.5: Secondary link reagent and detection system………………………………..29 
Table 2.6: Visualisation reagents………………………………………………………...29 
Table 3.1: Demographics for cross-sectional study……………………………………...40 
Table 3.2: Demographics for longitudinal-study………………………………………...40 
Table 3.3: The number of epithelial cells………………………………………………...45  
 
 
 
 
 
 
 
 
 
 
  
1 
Chapter 1 – Introduction & Literature Review 
1.1 Chronic obstructive pulmonary disease (COPD) 
COPD is a chronic disease with a complex condition that involves a frequent mix of airway 
and lung parenchymal damage. The Global Initiative for Chronic Obstructive Lung Disease 
(GOLD 2014) has characterised it by persistent airflow limitation that is usually progressive 
and associated with an enhanced chronic inflammatory response in the airways and the lung 
to noxious particles or gases. The definition of COPD has been a bit confusing and 
controversial due to its difficult diagnostic procedures over the years until recently. It was 
stereotyped as being caused by inflammation and considered analogous to asthma (1). The 
current definition of COPD does not include the terms chronic bronchitis and emphysema. 
Chronic bronchitis is the inflammation involving cough and sputum production that is not 
always necessarily associated with airflow limitation. Emphysema, defined as destruction of 
the alveoli, a pathological feature of several structural abnormalities in COPD that can also 
be found in people with normal lung functions (GOLD 2014). However, it is reflected by a 
decline in gas-exchange rate of the alveoli of the lungs by a measurement of the O2 (oxygen)
or CO (carbon monoxide) transfer rate (diffusion capacity) and can cause worsening of 
airflow limitation in COPD.     
1.1a Epidemiology and global impact of COPD 
According to World Health Organization (WHO) estimates, 210 million people are affected 
by COPD, with one hundred million deaths in the 20
th
 century. The WHO predicts that total
deaths from COPD will rise by 30% over the next decade, as smoking becomes increasingly 
epidemic in third world countries, which justifies an intense study of the disease that is 
currently lacking (2). The amount of one in 10 Australians aged 40 or over is affected by 
COPD (Burden of Obstructive Lung Disease- BOLD) (3). Alarmingly, only half of these 
affected people are aware that they have the condition. Australia has one of the highest 
COPD death rates in the developed world, putting the country in the 3
rd
 position of the 34
Organization for Economic Co-operation and Development (OECD)  countries (4). COPD is 
also the 2
nd
 leading cause of avoidable hospital admissions. In China, where more than 50%
of the men smoke, COPD is the leading cause of death in rural areas and 4
th
 in polluted urban
areas (5). In 2005, more than 126,000 adults in the United States died from COPD (6), while 
30% of all cancer deaths, including 90% of lung cancer deaths, can be attributed to tobacco 
use (Figure 1.1).  
2 
Figure 1.1 US cigarette use vs lung cancer deaths, 1900-2005 (Figure taken from Tobacco Outlook 
Report, Economic Research Service, US Department of Agriculture).  
1.1b Clinical physiology 
COPD is more than a “smoker’s cough” or “chronic bronchitis”. The diagnosis of COPD 
itself has to be confirmed by spirometry to demonstrate fixed airway obstruction. The 
presence of a post-bronchodilator ratio of forced expiratory volume in one second to forced 
vital capacity (FEV1/FVC) <70% confirms the presence of airflow limitation that is not fully 
reversible and allows a diagnosis of COPD. The degree of FEV1 decline defines the severity 
of the disease. The degree of Diffusing Capacity (Transfer Factor) decline caused by co-
existing emphysema is not included in the physiological definition, though if present it will 
contribute to the airflow obstruction and also exacerbate symptoms (7).  
Chronic cough, present intermittently or throughout the day, with or without chronic 
sputum production but without airflow obstruction, would formerly have been labelled 
chronic bronchitis, is now somewhat confusingly termed Stage 0 COPD (8). Stage 1 COPD 
with FEV1 still at 80% or above is also usually largely asymptomatic. As the disease 
progresses into Stage II moderate COPD with FEV1 between 50 and 80%, patients often 
experience shortness of breath, which may hamper their daily activities. As airflow limitation 
worsens and patients develop Stage III, or severe COPD, with FEV1 less than 50%, the 
symptoms of cough and sputum production and especially shortness of breath typically 
worsen. In addition, COPD frequently exacerbates. Exacerbations are usually precipitated by 
an airway viral infection; cough and sputum first get worse and then breathlessness and then 
acute wheezing (9). Such acute exacerbations frequently land the patient in the hospital, and 
unfortunately this may be the first time a diagnosis of COPD is made (10). Indeed, much 
more attention needs to be given to primary care in case of finding the onset of the earlier 
stages of the disease, in order to intervene and stop this disastrous progression.  
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COPD classically involves three overlapping phenotypes related to the disease in the 
in-series structural components of the lung, i.e. in large (central) airways, small (peripheral) 
airways, and more variably the lung parenchyma (Figure 1.2). Large airways are defined as 
>4mm in internal diameter; they subdivide many times to become small airways, defined 
when the inner diameter becomes <2mm. After a total of about 23 divisions, the airways give 
rise to clusters of alveoli (small air sacs) that form the gas exchanging membrane in close 
association with blood in the pulmonary capillaries. These gas-exchanging tissue structures 
plus supporting matrix and connective tissue “skeletal” elements form the parenchyma of the 
lung. Thus, in gross summary, the current standard understanding of the pathologic changes 
in COPD lungs involve inflammation and thickening of large airways (bronchitis), fibrosis 
and obstruction of small airways (obstructive bronchiolitis) and destruction of the lung 
parenchyma (emphysema) (Figure 1.2). The early stages of the development of COPD can be 
diagnosed clinically by measuring FEV1/FVC decline in early middle age of smokers and ex-
smokers (11).  
 
 
Figure 1.2 Respiratory tree (by Eraxion, iStock images) 
 
1.1c Risk factors associated with COPD  
 
COPD is largely caused by chronic exposure of the respiratory tract to harmful gases and 
particulates. Cigarette smoke is the major culprit in causing COPD in Western countries. The 
increased oxidant burden associated with depleted endogenous antioxidant defences occurs 
with each puff of a cigarette, containing more than 2,000 xenobiotic compounds and 10
15
 free 
radicals, causing damage to airways and lung epithelial cells (12). It has been demonstrated 
that cigarette smoking can induce pathological changes in the small airways even in smokers 
who have not yet developed symptoms of COPD (13). Smoking can activate many biological 
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processes at the cellular level which are potentially important in development of COPD 
(Figure 1.3) (14), and indeed chronic bronchitis. 
In addition to cigarette smoking, repeated exposure to environmental and/or 
occupational pollutants, chronic (or latent) infection, or an interaction between these can also 
cause COPD. In third world countries where wood, peat and dung etc. are the main sources of 
indoor heating and cooking, exposure to such biomass smoke is also a major cause of COPD. 
Chronic active asthma also frequently leads to irreversible airflow obstruction, an effect that 
is synergistic with cigarette smoke damage (15).  
 
Figure 1.3 The link between smoking and pulmonary pathology. 
Reproduced with permission (14). 
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1.2 Pathology of COPD 
 
1.2a Background to pathology 
Evolution of knowledge about COPD has occurred rapidly over the last few years. However, 
the history of COPD began in the nineteenth century with two landmark inventions- the 
stethoscope, by Laennec in 1819 and the spirometer, by Hutchinson in 1846. These offered 
new opportunities to discover the basic nature of COPD. Laennec was one of the first to 
recognise that a part of COPD is emphysema, where the lungs have lost their elasticity and 
empty poorly, with decreased elastic recoil pressure available to drive air out, accompanied 
by the abnormal destruction that begins in the small conducting airways, serving the alveoli 
of the lungs. “Perhaps both processes conspire to create the abnormality”, he stated (16). 
Hutchinson’s water spirometer allowed quantification of lung function, and he defined the 
vital capacity as “the number of cubic inches given by a full expiration following the deepest 
inspiration” (17). Spirometry was subsequently used to define the volume of air exhaled in 
the first second of maximum expiration and the ratio of this to the forced vital capacity 
(FVC), the forced expiratory ratio, has been used as the standard index of expiratory airflow 
obstruction.  
Studies into the details of airway remodelling in the airways of COPD patients date 
back to the 1950s and 1960s. The pathologist Lynne Reid in the UK was one of the first to 
quantitate airway remodeling in COPD. Her careful assessments noted excessive mucus, 
which was associated with both an increase in the number of goblet cells and hypertrophy 
and hyperplasia of the mucus glands, with metaplasia in the epithelium in smokers and 
COPD subjects (18, 19). More recent pathological interest in smoker/COPD airways has 
focused on the concept that this is an inflammatory disease. In the sub-epithelial lamina 
propria (LP) area (100 microns deep to the epithelial reticular basement membrane) 
significant increases in CD3+ and CD8+ T lymphocytes have been demonstrated (20). Saetta 
et al. also found increased expression of macrophages and T-lymphocytes in both the 
epithelium and in the LP in chronic bronchitis subjects (21). The role of these cells is not well 
defined.  Another type of inflammatory cell thought to be involved in airway remodelling in 
COPD is the mast cell, as these secretory cells can produce a number of bioactive factors 
including VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), 
and many other pro-inflammatory, pro-fibrotic, anti-angiogenic factors (22). Study on mast 
cells in COPD airways showed greater mast cell density in all COPD groups compared to 
control subjects (non-smokers with normal lung function) and has been related to hyper-
vascularity in smoking-related COPD subjects (23).  
Although, there is an increase in mast cells, lymphocytes, and macrophages, there was 
a significant reduction in total cellularity in the LP of smokers and COPD patients (24). 
Neutrophils are prominent in mucous glands in COPD airways and neutrophil elastase 
secreted by these cells is potentially involved in airway remodelling (25). Neutrophils and 
macrophages are prominent in airway washings. However, neutrophils were decreased in the 
epithelium, reticular basement membrane (Rbm), and lamina propria (LP) in COPD-current 
smoker subjects (26). Neutrophils only go up generally in the airway wall with inhaled 
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corticosteroid treatment (27). In the last decade medical research on COPD has developed 
substantially. Although COPD is a pan-airway process, small airway fibrosis and obliteration 
are implicated as main contributors to the decline in lung function (28). This decline can be 
compounded by the later development of lung parenchymatous breakdown or emphysema in 
some patients. Airway changes in COPD have probably been over characterised by 
‘inflammation’, and as analogous to asthma (1).  
However, a recent description of epithelial to mesenchymal transition (EMT), the 
activation of airway epithelial cells to develop migratory and fibrotic characteristics, is 
contributing to understanding the complex picture of at least the airway components of 
COPD (29). EMT is a remarkable process where transitioning motile epithelial cells digest 
through the basement membrane (BM) and reticular basement membrane (RBM) to become 
we believe sub-epithelial fibroblasts, which could contribute to fibrosis by releasing 
extracellular matrix (ECM) proteins (Figure 1.4). These fibroblasts are also thought to 
stimulate the epithelium to further stimulate EMT, thus contributing to a vicious cycle of 
small airway narrowing and airflow obstruction. Most of this supposition comes from what 
we know about EMT in other epithelial situations, and more research is needed to work this 
out for COPD. EMT could also contribute to other important aspects of airway pathology; in 
particular, it has been recognised elsewhere as promoting formation of a pro-malignant 
microenvironment for epithelia (30-33), and so may be relevant to the development of lung 
cancer (34). A recent genetic study on smokers, COPD and lung cancer implicated a robust 
genomic link between COPD, lung cancer and Hedgehog signaling (35). Another very recent 
cohort study found that cancer in COPD patients was frequent, and under-diagnosis of COPD 
among patients with lung cancer was very high (68.3%) (36). In non-small-cell lung cancer, 
active EMT is associated with the formation of cancer stem cells (37), drug resistance, and 
epidermal growth factor receptor mutations (38). A large body of evidence supports EMT 
contributing to cancer invasion and metastasis. According to current views on EMT in COPD 
airways may in addition be a crucial link between COPD itself and the development of lung 
cancer.      
7 
 
 
Figure 1.4 Epithelial-mesenchymal transition process. 
    RBM: Reticular basement membrane.   
     
1.2b Airway component 
Central/large airways (chronic bronchitis) 
The diagnosis of chronic bronchitis was pioneered and measured by the pathologist Reid in 
1954 (19). She measured the enlarged bronchial mucous gland layer and stated that chronic 
bronchitis is associated with inflammation involving the mucosal surface, submucosal glands, 
and gland ducts in smaller bronchi between 2 and 4mm in diameter (39).   
Chronic bronchitis is essentially an inflammatory condition and can be a significant 
part of COPD. Excessive cigarette smoking is one of the most critical factors in causing 
bronchitis. Also, inhalation of dusts, fumes, chemicals like silica, iron, steel, asbestos, carbon, 
kaolin and less commonly the fumes of chlorine at work can cause pathological changes and 
inflammatory response in chronic bronchitis (40). When chronic bronchitis is associated with 
the chronic airflow limitation in COPD, it involves mucus gland hypertrophy, mucus 
hypersecretion, squamous metaplasia, loss of epithelial cilia, goblet cell hyperplasia, and 
infiltration of inflammatory cells including CD45, CD8, macrophages, and neutrophils in the 
epithelium of peripheral airways (please refer to Figure 4 in the Saetta et al paper)  (41).  
Although worsening of inflammation in bronchitis can contribute significantly to the 
progression of COPD, a number of longitudinal studies have found that its presence alone 
does not predict the airflow limitation of COPD (11, 42). Analysis of lung tissues over the 
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years has indicated that the changes in the small airways and the small airway wall 
remodelling can couple with the inflammatory cells in large airways to induce COPD (43).   
 
Small airways (obstructive bronchiolitis) 
Macklem and Mead were the first to introduce the resistance in small airways in 1967 (44). 
Soon after, Hogg and his colleagues suggested that small airway abnormalities can contribute 
significantly to airflow limitation in COPD (28, 39, 43, 45-49). There is an increased interest 
in small airway disease and some new insights have been gained over recent years on their 
contribution to the clinical expression of COPD.  
Hogg’s extensive study found that inflammation in small airways is an important 
feature of COPD pathology. However, interestingly he also showed that tissue remodelling in 
the small airways, including small airway wall fibrosis and obliteration, were the most 
important independent factors for the aetiology of COPD, rather than inflammation (please 
refer to Figure 1 in the Berge et al paper) (50). The exact mechanisms behind the small 
airway damage still remain obscure. Several possible mechanisms have been suggested. 
Chronic inflammation can play an integral role in stimulating fibrotic changes in the 
peripheral airways (50). The ongoing inflammation is responsible for an increased production 
of transforming growth factor beta (TGFβ). TGFβ is a fibrogenic multifunctional cytokine 
that is very important in the cell organization, development, proliferation, and immunology 
(51-53). Long term exposure to cigarette smoke itself can also cause increased production of 
TGFβ, pro-fibrotic growth factors such as connective tissue growth factor (CTGF), platelet-
derived growth factors (PDGF) and TGFβ induced transcription factors such as Smad 
proteins (54). These changes can lead to altered extracellular matrix (ECM) structure of the 
airway wall in COPD subjects.       
 
Lung parenchyma component (emphysema) 
Hogg et al examined small airway remodelling and alveolar destruction in emphysema in 
COPD subjects using micro-computed tomography (micro-CT) (55). They investigated the 
number of small airways, their minimal cross-sectional lumen area, and lung parenchyma in 
four lungs removed from patients with very severe COPD and four unused donor lungs as 
control by using micro-CT scanning. They found a 10-fold reduction in the number and a 
100-fold reduction in the minimal cross-sectional lumen area of the small airways in COPD 
lungs, both in areas with and without emphysematous destruction. These results suggest that 
the narrowing and obliteration of small airways begin in the COPD group prior to the onset of 
emphysematous destruction. This again implies the importance of small airways as targets for 
disease prevention and treatment.  
Chronic inflammation caused by cigarette smoke plays a significant role in causing 
emphysema (56). The ongoing inflammation leads to destruction of airspace structure and 
disturbance of normal maintenance of alvelolar structure by mobilization of inflammatory 
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cells to the lungs and the release of potentially destructive cytokines (56). Inflammation also 
stimulates apoptosis in alveolar cells and there are good evidences that support the additional 
role of apoptosis in generating emphysema (56, 57). Consequently, these lung parenchymal 
destructions cause a reduced elastic recoil pressure that is available to push the air out of the 
lungs. This may also lead to dynamic airway collapse. These pathological changes in 
emphysema may eventually result in decreased ventilator function and hampers optimal 
airflow (58).     
 
1.3 Epithelial-mesenchymal transition (EMT) in COPD 
 
1.3a Centre of Research Excellence for Chronic Respiratory Disease (CRE) Breathe 
Well group work  
 
In addition to the thickening and squamous metaplasia of the epithelium that are well 
described in COPD airways, CRE Breathe Well group recently highlighted changes in the 
Rbm of the epithelium, with fragmentation and ‘cleft’ formation, and increased cellularity in 
larger airway biopsies (1, 59). These changes are highly reminiscent of the classic 
descriptions of EMT (59, 60). Indeed, it is difficult to know what else such changes could 
represent, and they are very different from the well-established changes in adult asthma (61). 
Further studies on airway biopsies from COPD patients confirmed up-regulation of various 
proteins well established to be bio-markers of EMT. Thus, we observed cells staining positive 
for the expression of matrix metalloproteinase (MMP) -9, the proteolytic enzyme that is one 
of the strong associates of EMT, the fibroblast protein S100A4 (also called fibroblast-specific 
protein, FSP-1, one of the most commonly used EMT bio-markers), and the mesenchymal 
protein vimentin (59). These cells were present both in the basal epithelium (BE) and clefts in 
the Rbm, and were shown not to be macrophages, neutrophils, dendritic/Langerhans cells or 
lymphocytes infiltrating from below. They seem to be of epithelial origin as they double-stain 
for S100A4 and cytokeratin (an epithelial marker) (62). The epithelium was shown to be in 
an activated state, with cells stained highly positively for epidermal growth factor receptor 
(EGFR) (29). These histological features were all present in physiologically normal smokers, 
and in COPD ex-smokers, but were most marked in COPD current-smokers (63, 64). We also 
noted vessel changes, with hyper-vascularity of the Rbm and epithelium and hypo-vascularity 
in the LP, but these were evidently more smoking related than COPD related (65). 
After CRE Breathe Well publications on larger airway biopsies, CRE and other 
different groups have shown that similar changes of EMT are also present in small airways 
(64, 66, 67), but preliminary results suggest that EMT in small airways is not accompanied by 
hyper-vascularity (64).  
1.3b Other groups’ work  
The Milara et al. study also demonstrated that cigarette smoke extract (CSE) can induce EMT 
in primary human bronchial epithelial cells (HBECs) through modulating the TGFβ pathway 
and intracellular adenosine cyclic monophosphate (cAMP) levels in vitro (67). In a similar in 
vitro model, Wang et al. observed a significant correlation between urokinase plasminogen 
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activator receptor (uPAR) and vimentin expression indicating a potential uPAR-dependent 
signaling pathway for CSE-induced EMT(66). Another in vitro study by Cȃmara and Jarai 
demonstrated that EMT could be induced by TGFβ through the Smad2/3 pathway in primary 
human bronchial epithelial cells. The TGFβ stimulated EMT was enhanced by the presence 
of extracellular matrix (ECM) protein fibronectin and tumour necrosis factor α (TNFα) (68).  
Interestingly, the non-neuronal cholinergic system is also getting remarkable attention 
recently in playing a possible role in inducing EMT in airway diseases. Acetylcholine (ACh), 
one of the principal neurotransmitters that is synthesised by certain neurons, is a key player in 
the nervous system. However, recent study has identified ACh and acetylcholine receptors 
(AChR) in many other non-neuronal cells and tissues, including airway epithelial cells (69). 
The use of anticholinergic therapy in COPD is widely used based on the parasympathetic 
activity that is increased in the airway inflammation (70). However, Gosens et al’s novel 
study also found that dysfunction of the non-neuronal cholinergic system of ACh can also 
play a significant role in the pathophysiology of COPD (71). Muscarinic acetylcholine 
receptors (mAChRs) are extensively expressed in the airways and are associated with airway 
remodelling, including airway smooth muscle thickening, differentiation, profound 
proliferation, collagen secretion, and fibroblast to myofibroblasts transition (71, 72). A recent 
study by Milara et al in vitro demonstrated that a new long-acting muscarinic receptor 
antagonist called aclidinium inhibits human lung fibroblast to myofibroblasts transition 
induced by carbachol, an analogue of ACh and TGF-β1 stimulation (73). Furthermore, they 
also reported that the non-neuronal cholinergic system is involved in cigarette smoke-induced 
lung fibroblast-to-myofibroblast transition that is inhibited by aclidinium (74). Another 
anticholinergic, tiotropium, is also reported to inhibit MMP production from lung fibroblasts 
induced by TGFβ through the suppression of Smad signalling and inhibiting protein 
phosphorylation (75). These evidences suggest the potential effects of non-neuronal 
cholinergic system in TGF-β pathway and its role in EMT. Yang et al is one of the first to 
explore the role of ACh and pathway involved in EMT in airway diseases (76). This study 
pointed towards a possible crosstalk between mAChR activation and TGFβ expression in 
stimulating EMT. ACh may function via M1 and M3 receptors in the airways through the 
Smad2/3 and ERK signalling pathways (76).          
Despite the in vitro work looking at the pathways that can potentially drive EMT in 
human airways, the drivers and pathways of EMT in vivo in the airways of COPD patients 
still remain to be confirmed. 
 
 
 
  
11 
 
1.4 Definition of EMT 
1.4a What is EMT? 
Elizabeth Hay from Harvard University initially described a process she termed ‘epithelial–
mesenchymal transformation’ in a model of chick embryo primitive streak formation (77). In 
time, the term ‘transformation’ has been replaced with ‘transition’, reflecting its possible 
reversibility in a two-way process (78). Recent interest in EMT stems less from its 
developmental importance, but more from emerging evidence of its involvement in 
promoting organ fibrosis (78), tumor formation and cancer metastasis (79). EMT is an 
example of what evolutionary biologists call ‘exaptation’: alteration in the function of a basic 
trait to provide new functions under new circumstances. Thus, insults to epithelial cells by 
cigarette smoke can activate EMT (67), changing cellular identity and promoting sustained 
tissue disruption that can potentially stimulate fibrosis, compromise tissue integrity and organ 
function (80) and/or enhance oncogenesis (78). Given this background, EMT has been 
classified into three subtypes based on the context (60). Type 1 EMT is associated with 
gastrulation and embryogenesis during organ formation (physiological). Type 2 EMT can 
also be a normal physiological process of tissue repair to generate fibroblasts in wound 
healing. However, it can result in organ destruction if it is persistent in the context of an 
ongoing pro-inflammatory insult. For example, the alveolar epithelial cells in idiopathic 
pulmonary fibrosis are morphologically abnormal, showing altered cytokeratin expression 
and producing ECM remodeling proteins such as MMPs. They have been shown to express 
mesenchymal markers in lung biopsies from idiopathic pulmonary fibrosis patients, and it has 
been proposed they contribute to fibrosis in vivo (81). Type 3 EMT is associated with 
epithelial tumors: both as a pro-tumor mechanism and also then subsequently used by 
epithelial tumors to invade and metastasize. This more sinister form of EMT Type 3 is 
associated with accompanying hyper-vascularity (1, 60, 65). In this context, it needs to be 
noted that epithelial tumors are very common and indeed make up 90% of human cancers, for 
example, breast, prostate, lung (airway), bowel, esophagus, stomach, pancreas etc., and EMT 
may be the unifying underlying pathological process which makes sense of this particularity 
(30-33, 79). 
 
1.4b Potential EMT drivers in COPD 
 
Epithelial ‘stress’, however caused, is thought to activate EMT, creating critical and self-
perpetuating pro-fibrotic, pro-remodeling and pro-cancer events. These events are complex, 
involving potential activation of a number of signaling pathways, but converging on several 
prominent transcription factor families; some of these (e.g., Twist, Snail, Slug) are EMT 
specific while others (e.g., β-catenin and Smads) are somewhat less specific, but still 
potentially involved. Although there is no research data yet identifying the drivers involved in 
the process of driving EMT in COPD, the plausible pathways are reviewed below. 
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1.5 Transforming growth factor beta 
 
TGFβ is one of the most important and sophisticated tissue and cell-regulatory networks and 
has been implicated in driving EMT (Figure 1.5) (82, 83), particularly the isoform TGFβ1. It 
may be a ‘master switch’ of fibrogenesis in many organs, including the lung (81, 84, 85). 
TGFβ1 has been one of the most widely studied cytokines/mediators of EMT (53).  
 
 
1.5a Smads as transcription factors of TGFβ signaling  
 
Studies on human alveolar and bronchial epithelial cell lines have shown that TGFβ1 can 
induce EMT via Smad2 activation (Figure 1.5) (86, 87). Evidence for a direct role for TGFβ 
in the effector end of EMT in the lung in vivo was given by the overexpression of active 
TGFβ1 in myofibroblasts in injured lungs, associated with EMT in situ (88). EMT in 
response to TGFβ1 ligand binding is thought to be mediated predominantly via Smad-
transcription factors (82, 89).  
 
Smads are classified into three subclasses, that is, receptor regulated Smads (R-
Smads), common partner Smads and inhibitory Smads. Smad2 and Smad3 are R-Smads, 
activated by TGFβ Type I receptors. In contrast, Smad6 and Smad7 function as inhibitory 
Smads, while Smad4 serves as the common partner Smad in mammals, that is, it combines 
with R-Smads to activate them (90), and the complex translocates to the nucleus to act as 
transcription factors. 
TGFβ transmits its signals through its serine-threonine kinase receptors, which upon 
activation are internalized into early endosomes where it associates with ‘Smad anchor for 
receptor activation’ which modulates the formation of complexes with Smad2 or Smad3 (81). 
The R-Smads are then phosphorylated by the receptor, which induces their association with 
the common partner Smad4 for translocation to the nucleus (Figure 1.5). In the nucleus, this 
Smad complex binds to promoter regions of target genes in further association with various 
other DNA-binding proteins (90). 
 
Recent studies suggest that the majority of TGFβ1 target genes are controlled through 
Smad3-dependent transcriptional regulation (91). Overexpression of inhibitory Smad7 
consistently blocks Smad3-dependent EMT in vitro and in vivo (92). Smad2 and/or Smad3 
are also associated with EMT-related tumor progression models (93). However, it has not yet 
been investigated whether the Smad signaling pathway is active in COPD airways. 
 
1.5b Alternative (non-Smad) pathways of TGFβ signaling 
 
Smad-independent signaling has also been implicated in EMT (89), although less is known 
about it or its relevance. Non-Smad-dependent pathways implicated in TGFβ-elicited EMT 
include activation of extracellular signal-regulated kinases (Erk)/mitogen-activated protein 
kinases (MAPK), Rho GTPases and the phosphatidylinositol-3-kinase /Akt pathways (Figure 
1.5) (81, 82), although these are less established compared to Smad dependent pathways and 
have been reported mainly in in vitro studies (94-96). However, MAPKs, originally called 
Erks, are required for the induction of cell motility and disassembly of cell adheren junctions 
after TGFβ stimulation. The TGFβ-stimulated Erk signal also regulates transcription of genes 
which are known to function in the modulation of integrin-based cell matrix adhesion to 
promote cell motility (97). Erks regulate target gene transcription through activating its many 
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downstream transcription factors, such as ELK1 (a transcription activator), to influence EMT 
(97, 98). 
 
To add to this complexity, there may be significant crosstalk between the Smad-
dependent and Smad-independent pathways, with non-Smad proteins modulating Smad 
activity and vice versa. But the Smad independent pathways have not yet been investigated in 
EMT in the airways. 
 
 
 
 
 
 
Figure 1.5. A simplified schematic diagram showing the major potential drivers of epithelial–
mesenchymal transition. These pathways are complex and inextricably interconnected. The Smad 
pathway for TGFb signaling acts through formation of a complex between Smad2/3 and Smad4. The 
complex then moves to the nucleus and stimulates transcription of their target genes. Sharp arrows 
denote activation/upregulation and blunt arrows denote inhibition/downregulation. BM: Basement 
membrane; BMP: Bone morphogenic protein; DVL: Disheveled; ECM: Extracellular matrix; Fzd: 
Frizzled receptors; Gli: Glioma-associated oncogene family of transcription factors; GSK-3b: 
Glycogen synthase kinase; Hh: Hedgehog; PI3K: Phosphatidylinositol-3-kinase; ILK: Integrin-linked 
kinase; LEF-1: Lymphoid-enhancer-binding factor-1; LRP: Low-density lipoprotein receptor-related 
protein; p38 MAPK: Mitogen activated protein kinase; Ptc: Patched receptor for Hh signaling; SMO: 
Smoothened; TGFβ: Transforming growth factor beta; uPAR: Urokinase plasminogen activator 
receptor. Adapted from (83). 
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1.6 Other potentially primary transcription factor families 
 
1.6a Snail1, Snail2 (Slug), Twist in EMT 
 
There is evidence for a direct link between TGFb1 signaling and induction of Snail/Slug 
expression, thought of as specific ‘primary’ transcription factors for EMT induction, acting 
through β-catenin release (99-101). There is evidence that the Snail family transcription 
factors promote EMT through β –catenin transcription encouraging its accumulation and 
availability to act as a pro-EMT transcription factor (102). Furthermore, Snail and Slug are 
strong epithelial cadherin (E-cadherin) repressors implicated in inducing EMT through 
accumulation of β-catenin by releasing it from its role in inter-cell-adhesion complexes. 
These transcription factors are differentially expressed in different tissue contexts (81), and 
whether one or both are involved in COPD airway disease has not yet been investigated. 
 
Twist is another transcription factor regarded as a ‘master’ regulator of embryonic 
morphogenesis and is also thought to play an essential role in up-regulating EMT, at least in 
metastatic and invasive carcinomas (103). Again, it seems to work at the levels of E-cadherin 
suppression and β-catenin accumulation. Its potential role in airway EMT deserves attention. 
 
 
 
Figure 1.6. Smad and non-Smad pathways in transforming growth factor β-activated epithelial–
mesenchymal transition. EMT: Epithelial-mesenchymal transition; PI3-K: Phosphatidylinositol 3-
kinase. 
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1.7 Wnt pathway in EMT 
 
The name Wnt is a combination of Wg (Wingless) and int (integration) genes and stands for 
Wingless-related integration site (104). Wnt signaling was originally identified in playing a 
role in carcinogenesis, but the signaling pathway since then has been well characterized in 
embryonic development, including cell fate specification, cell proliferation, differentiation 
and epithelial–mesenchymal interactions (105, 106). Wnt ligands are a large family of 
secreted glycoproteins and highly hydrophobic. In vertebrates, there are 19 different Wnt 
proteins whose expression is regulated during development. Wnt ligands bind and transmit 
their signal across the plasma membrane through binding to both Frizzled receptors and low-
density lipoprotein receptor-related protein (LRP) (107). 
 
1.7a Role of Wnt & β-catenin 
 
Activation of EMT is classically characterized by decreased production of E-cadherin, which 
is part of the adheren molecular aggregates responsible for epithelial cell–cell adherence. A 
second component of adheren complexes is β-catenin, which plays an integral part in adheren 
junctions by linking E-cadherin to the cytoskeleton. When E-cadherin is less available, for 
example, if its nuclear transcription is inhibited, the adheren complex breaks up and free 
cytosolic β-catenin may accumulate (107). β-catenin is known to be a key player in the Wnt 
pathway and has also been implicated as a driver in EMT, by itself potentially acting as a 
transcription factor or transcriptional co-activator of other transcription factors (108). This 
occurs when cytosolic β-catenin accumulates. However, free cytosolic β-catenin is normally 
kept suppressed and inactive in epithelial cells through a strategic enzyme, glycogen synthase 
kinase-3β (GSK-3β), leading to its phosphorylation and subsequent ubiquitination and 
proteosomal degradation.  
 
Wnt ligand activation of its receptor complex leads to phosphorylation of LRP, again 
by GSK-3β, resulting in recruitment of the cytosolic proteins Dishevelled and Axin. The 
formation of Frizzled - Dishevelled and LRP-Axincomplexes results in active release of β-
catenin from E-cadherin complexes into the cytoplasm and at the same time inhibits the β-
catenin phosphorylation by GSK-3β. The cytoplasmic accumulation of b-catenin is therefore 
complex and has several causes, but this accumulation enables β-catenin to move into the 
nucleus to act as an important pro-EMT nuclear transcription factor (Figure 1.5) (102, 107-
109). It has also been suggested that the formation of complexes between the members of 
Snail family of transcription factors, β-catenin and another transcription factor known as 
lymphoid enhancer factor can induce EMT under TGFβ stimulation (102). The potential role 
of crosstalk between TGFβ and Wnt signaling pathways in mediating EMT in pathological 
events, especially in our case COPD, remains to be determined. 
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1.8 Other pathways implicated in EMT 
 
1.8a Hedgehog pathway 
 
Another important signaling pathway described as inducing EMT is Hedgehog (Hh) signaling 
(Figure 1.5), which was initially discovered in Drosophila by Wieschaus and Volhard (110). 
Hh is a major regulator of cell proliferation, differentiation and tissue polarity. The Hh family 
consists of three Hh proteins, including Sonic Hedgehog, Desert Hedgehog and Indian 
Hedgehog (107). Binding of Hh ligands to their receptors causes activation of a family of 
transcriptional factors through complex cascades. This leads to the up-regulation of Wnt 
protein, β-catenin and bone morphogenic protein accumulation in the cytoplasm.  
 
Wnt and Hh signaling are both mediated by the G-protein coupled Frizzled receptors, 
and both pathways prevent phosphorylation-dependent proteolysis of β-catenin. In addition, 
the molecules involved in Wnt signaling such as GSK-3β also regulate Hh signaling, 
suggesting crosstalk between the two potential pathways. Emerging evidence suggests the 
activation of Hh signaling in numerous human cancers, including lung cancer (110). The 
available literature on Wnt and Hh signaling shows that these pathways can be crucial for 
driving cancer cells toward aggressiveness, but relevance to COPD has not been investigated.  
 
 
1.8b Integrin-linked kinase pathway  
 
The important potential role of integrin-linked kinase (ILK) signaling (Figure 1.5) in EMT 
and associated tumor progression has been described frequently over the last few years. ILK 
acts as a growth factor signaling protein and regulates a diversity of processes such as 
proliferation, apoptosis, survival, invasion and angiogenesis (111). Accumulating evidence 
suggests that in human malignancies, ILK activity is overexpressed. A recent study on the 
role of ILK in lung cancer aggressiveness showed over expression of ILK which promoted 
cell invasion, migration and metastasis, associated with acquisition of an EMT phenotype 
(112). ILK, perhaps in combination with TGFβ, induces the de novo expression of several 
integrins, such as a5β1, avβ3 and avβ6, which enhance the migration and invasion of 
carcinoma cells, particularly in conjunction with MMPs and fibronectin (113). ILK, TGFβ 
and Wnt signals (Figure 1.5) are interconnected and converge at the activation of a number of 
transcription factors which leads to the activation of EMT transcriptional programs, but has 
not been studied in COPD airways.  
 
 
1.8c uPAR pathway 
 
A recent study by Wang et al. showed that uPAR signaling can also play a role in EMT (66). 
Urokinase was originally isolated from human urine, but can also be present in several other 
locations including the ECM. The main physiological substrate for urokinase plasminogen 
activator (uPA) is plasminogen. When uPA, a serine protease, binds to uPAR, plasminogen is 
activated to form plasmin (Figure 1.5). Activation of plasmin triggers a proteolytic cascade 
that can participate in remodeling of ECM, degrading components of BM and hence, 
allowing cells to move across and through these barriers (66, 114). Binding of uPA to uPAR 
can induce EMT through activating a number of cell-signaling factors, including 
17 
 
phosphatidylinositol 3-kinase (PI3k), Src family kinases, Akt, ERK/MAPK and myosin light 
chain kinase (114-116). Among them, only the PI3k/Akt pathway has been studied a little in 
uPAR signaling in EMT. Activation of PI3k signaling catalyses the formation of 
phosphatidylinositol 3,4,5-phosphate,which can influence cell morphology through its effect 
on actin cytoskeleton reorganization and migration (114). Another mechanism by which PI3k 
may also be involved is through the activation of Akt, which can promote cell invasion (114) 
and regulate the activity of several transcription factors, including NFkB (nuclear factor 
kappa B) that binds to the DNA sequence and can directly/indirectly induce EMT, sometimes 
through intermediate transcription factors Snail or ZEB-1/2 (Figure 1.5)) (117).  
 
 
1.9 Evidence of EMT drivers in human airways  
 
In the lungs, a significant correlation was found between the increased expression of TGFβ 
and the increased thickness of the BM and the increased number of fibroblasts in mucosal 
biopsies in both asthma and chronic bronchitis (51). In this study, TGFβ was localized to both 
structural cells such as epithelial cells and fibroblasts as well as to eosinophils (51). The 
expression of TGFβ1 mRNA in small airway epithelium from smokers and patients with 
COPD was significantly higher than in non-smoker controls (84). Furthermore, among 
smokers with COPD, the TGFβ1 mRNA levels correlated positively with the extent of 
smoking history (pack-years) and the degree of small airway obstruction (84). Our group 
showed an increased expression of vessel-associated TGFβ in the bronchial RBM in COPD 
but also in normal smokers (118). We did not find an increase in TGFβ in the epithelium in 
large airway biopsies, so the story of how TGFβ may be operating in COPD needs to be 
clarified.  
 
Apart from TGFβ, there has been little work in airway tissue on potential drivers of 
EMT. Although Wang et al showed uPAR signaling pathway to be present in small airway 
tissue from COPD subjects (66), there has not been adequate focus on other potential drivers 
of EMT. There is a great possibility that different signaling pathways may be participating in 
the progression of COPD disease at different stages and in anatomically different sites, for 
example, large versus small airways. A lot more research work needs to occur.  
 
 
1.9a Vessel-associated TGFβ activity in COPD-smokers        
 
As I have stated before, TGFβ is a cytokine with plethora of functions including 
angiogenesis, in numerous cells and tissues including epithelial, endothelial, hematopoietic, 
neuronal cells and connective tissue. Moreover, platelets and megakaryocytes are an 
abundant source of TGFβ1 in humans (119). Of the several functions of TGFβ, stimulation of 
angiogenesis should be highlighted as it can be associated with human disease, particularly 
cancer. TGFβ can act as a direct/indirect angiogenic factor promoting angiogenesis through 
the downstream induction of other cytokines, such as vascular endothelial growth factor 
(VEGF), that is a potent regulator of angiogenesis in various malignancies (119). The study 
published by the Kranenburg and colleagues has suggested that bronchial vascular changes 
may occur in COPD, they did this by demonstrating the VEGF expression in vascular and 
airway smooth muscle cells, epithelial cells, and macrophages using immunohistochemistry 
(120). On the other hand, the endothelial cells only showed VEGF receptor expression, but 
not VEGF, indicating the endothelial cells being effector cells for VEGF to act on rather than 
an important autocrine source (120). A number of factors relevant to COPD have been shown 
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to increase VEGF expression and release, these include cigarette smoke (121) and cytokines 
such as TGFβ (122). In addition, TGFβ receptors are suggested to play a key role in the 
pathogenesis of COPD through their Smad pathways (39). Hence, there could be an 
important link between Smad expression through the angiogenic effects of TGFβ in COPD as 
well as in lung cancer that needs to be addressed. My study on Smads predominantly focuses 
on this scenario.            
 
The study by our group previously found that in smokers with COPD there was a 
suggestion that the increase in blood vessels in the Rbm was related to both VEGF and 
TGFβ1 (118). This relationship was not evident in the COPD ex-smokers or normal lung 
function smokers group with only the TGFβ increase in Rbm vessels implying that in the 
COPD-smokers group the vascularity is driven by both TGFβ and VEGF whereas in the other 
two groups it is only related to TGFβ (118). EMT and fibrosis in response to TGFβ is 
stimulated predominantly through Smad dependent (mainly Smad2 and Smad3) pathways 
(81). Smads are intracellular proteins that act as transcription factors that transduce 
extracellular signals from TGFβ to the nucleus where they activate gene transcription (123). 
The name SMAD is a portmanteau of the two proteins: the Drosophila protein, mothers 
against decapentaplegic (MAD) and the Caenorhabditis elegans protein SMA (from gene 
sma) (124).   
 
In the Smad regulated pathway, TGF-β1 signals are transduced by transmembrane 
serine/threonine kinase type II and type I receptors. The receptors are internalised into early 
endosomes where Smad anchor for receptor activation (SARA) modulates formation of 
complexes with Smad2 or Smad3. There is another inhibitory type of Smad, Smad7, which 
can inhibit TGF-β signaling through inhibition of TGF-β receptor I phosphorylation (125). 
When there is no inhibition, Smad2 and Smad3 are then phosphorylated at serine residues by 
the type I receptor. Phosphorylation induces their association with Smad4 and translocation 
to the nucleus where they stimulate TGFβ -responsive gene transcription (81). 
        
 
Originally, it was found that TGFβ gene transcription can endogenously produce TGFβ that 
then acts as an autocrine negative growth regulator (126). Hence, it was hypothesised that it 
may inhibit proliferation and consequently, may act as an inhibitor of tumor progression 
(127). Conversely, some studies have found that TGFβ can potentially stimulate proliferation 
(128, 129). Therefore, this discrepancy may possibly be explained by the concentration of 
TGFβ within the cell, with low endogenous concentration of TGFβ resulting in proliferation 
and high endogenous concentration inducing growth arrest (127). In this case, the role of 
Smads as transcription factors of the TGFβ pathway may become important. Low 
intercellular TGFβ concentration may activate the receptors and thereby allow the Smad 
pathway to be utilised leading to more TGFβ release and proliferation of the cell. Because of 
this dual role of TGFβ as a pro-oncogenic factor in addition to its tumor suppressor role, 
members of the TGFβ signaling pathway, such as Smads are considered as predictive 
biomarkers for disease progression, particularly tumorigenesis (127). An important aspect of 
TGFβ is its ability to induce EMT and numerous studies are currently investigating EMT 
markers and its relevance in identifying airway pathology in COPD (62, 66, 67).  
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1.10 Aim  
The aim of this study was to study the immunostaining of the key transcription factor, 
phosphorylated Smad2/3 (pSmad2/3) in order to study TGFβ signaling, in the COPD 
airways, epithelium and underlying tissues.  
 
1.11 Rationale of study 
Transforming growth factor beta (TGFβ) is a multifunctional cytokine that is present in many 
tissues and cells in the human body (53, 82, 87, 92, 109, 130-132). There are only limited 
data available on its role in COPD. It has been shown that TGFβ1 immunostaining in COPD 
airways were increased in the bronchial reticular basement membrane in smokers, and 
correlated with an increased in vascularity, especially in those who are current smokers (118). 
One important manifestation of EMT activity through TGFβ pathway involves up-regulation 
of specific key transcription factors, such as Smads, particularly phosphorylated Smads (92, 
132, 133). Hence, immunostaining of the pSmad2/3, which is most commonly seen, was 
measured and analysed to determine the possible TGFβ pathway in COPD airways and their 
involvement in pathogenesis. 
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Chapter 2 – Materials and Methods 
 
2.1 Subjects and study design  
Informed consent was received from all subjects. Two main studies were designed to 
examine the immunostaining of pSmad2/3, the first one was cross-sectional and the second 
one was longitudinal.  
The cross-sectional study involved an analysis of pSmad2/3 immunostaining in 
COPD subjects and smokers against controls, using lung biopsies obtained at fiberoptic 
bronchoscopy. The study was approved by the Alfred Hospital in Melbourne and the Royal 
Hobart Hospital (RHH) Ethics Committees and participants were recruited by advertisement 
in local newspapers and placement of posters in the clinic waiting areas in the hospitals and 
on the notice boards. Tissue collection was started in Melbourne, but was continued in Hobart 
when Professor Walters moved his team.   
Endobronchial biopsies from 15 healthy non-smokers as controls (NC), 13 smokers 
with normal lung function (NLFS), 15 COPD current-smokers (COPD-CS) and 14 COPD ex-
smokers (COPD-ES) were analysed for the study. Any participant with a history of any other 
respiratory disorder was excluded. They all were aged above 50. Their cigarette smoking 
histories were recorded as pack years (by multiplying the number of pack of cigarettes 
smoked per day with the number of years the person has smoked, divided by 20). Their lung 
function results were measured as percentage predicted forced expiratory volume in 1 second 
(FEV1) and ratio of FEV1 to forced vital capacity (FVC) as percentage.  
Finally, a longitudinal study was performed in matched COPD subjects where Smad 
expression was measured before and after the inhaled corticosteroid (ICS) fluticasone 
propionate (0.5mg/twice daily) or placebo therapy for 6 months (2:1 ratio of ICS vs placebo), 
as part of a study of airway remodelling in COPD and response to corticosteroid. For the 
second time point in the original study there were 11 treated and 4 placebo from the COPD 
current cohort, and there were 8 treated and 6 placebo from the COPD ex cohort. However, 
for this component of the study for the COPD current smokers there were only material from 
7 of the subjects of which 6 were treated with ICS and 1 was from the placebo arm, for the 
COPD ex-smokers there were only materials from 5 of the subjects of which 3 were treated 
with ICS and 2 were treated with placebo.   
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2.2 Statistics 
 
A Shapiro-Wilk normality test was performed in SPSS and indicated all 4 groups 
significantly deviated from normal distribution. Skewed histograms and a normal Q-Q plot 
also showed non-symmetric distribution. The Kruskal-Wallis H test in SPSS was then used to 
determine if there were statistically significant differences between the different groups. 
Based on the output of the Kruskal test, a Tukey post hoc test was used to determine where 
the differences lie between the groups. All analyses were performed using SPSS statistics. 
Two-tailed p values <0.05 were considered as significant. 
 
2.3 Bronchoscopy  
The laboratory facilities used for this research project included standard histology labortory 
equipment, a Dako immunostainer (Denmark), and computerised image analysis using Leica 
DM2500 light microscope (Switzerland) and Image Pro-Plus 7 software (Media Cybernetics-
the USA) in medical science 1 (MS1) building at University of Tasmania (UTAS) as part of 
the Centre of Research Excellence (CRE) Breathe Well infrastructure.  
Subjects fasted overnight before the bronchoscopy. After the subjects were sedated 
with intravenous administration of midazolam (5-10mg) and fentanyl (50-100microgram) and 
topical lignocaine (200-400mg) to throat, larynx, and airways, bronchoscopy was conducted 
by respiratory physicians from the Department of Respiratory medicine in both hospitals. 
Prior to bronchoscopy, subjects were pre-medicated with nebulised salbutamol (5mg) 
approximately 15-30 minutes before the bronchoscopic examination. This procedure was 
done using a flexible fiberoptic bronchoscopy called Olympus Video-bronchoscope (Japan) 
instrument. Eight endobronchial biopsies (EBB) were taken from subcarinae of uninvolved 
contralateral bronchus of each subject using alligator forceps inserted parallel to 
bronchoscope. Blood pressure, pulse rate, and saturation of arterial oxygen were monitored 
during the procedure. Saline solutions were used to wash alligator forceps after each biopsy.        
 
2.4 Processing of biopsies 
4 biopsies were taken for each subject for paraffin (Sigma-Aldrich, Australia) embedding in 4 
% buffered formalin supplied by the RHH. They were fixed at room temperature (RT) for 2 
hours and then placed in 50% alcohol overnight or over the weekend if taken on a Friday. 
Biopsies were placed between two half sheets of “slide insert paper” in cassette with foam on 
either side. This makes biopsies easy to find prior to embedding. Cassettes were then placed 
in the automated processor Leica ASP200S as shown in Figure 1 and they were processes 
using xylene (Recochem Inc Australia), and 100% ethanol (Sigma-Aldrich, Australia) 
followed by 95% then 70%.   
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Figure 2.1: Automated Processor Leica ASP200S  
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Once the above processing was complete, the retort was drained and cassettes were 
removed to embedding centre (Figure 2.2) that was preheated to melt embedding wax and 
heat cassette holding chamber half an hour prior to the processor completing its cycle. 
Cooling plate, fume extractor and lights were switched on. A single biopsy was placed in a 
small steel mould. While using small moulds to fill with hot paraffin wax, a pair of forceps 
was used to hold biopsy in centre of mould and mould was moved onto small cooling plate 
on embedding centre. Biopsy was quickly and gently tamped and then labelled cassette was 
placed (A, B, C or D, initials, date of birth and reception date) on top of mould and filled with 
hot wax. Mould was moved onto large cooling plate and allowed to cool for half an hour 
prior to removing mould from embedded biopsy. Excess wax was removed from edges of 
biopsy by using heating plate for this purpose. Prior to cutting for Haematoxylin and Eosin 
(H&E), paraffin embedded tissue blocks were allowed to cool overnight before being stored 
at room temperature. 
 
 
 
 
Figure 2.2: RA Lamb Embedding Centre 
 
 
24 
 
2.5 Sectioning of paraffin-embedded tissue blocks: 
Paraffin-embedded tissue blocks of biopsies were effaced using the Leica RM2255 
microtome (Leica Microsystems, Germany) shown in Figure 2.3. Then paraffin blocks were 
sectioned at 3.5 microns either after cooling in –20 degree freezer or on ice blocks for 5-10 
minutes to assist with sectioning using the same microtome. Cut sections were transferred 
onto a deionised water bath containing one drop of Tween 20 (product code - ICN 103168) 
(to allow sections to unfold and spread out) at approximately 50°C. Two cut sections were 
picked up and mounted on each slide separated by 40-50 microns on Dako “IHC” (brand 
name) charged slides. Prepared slides were dried overnight at 37°C in incubator. 
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Figure 2.3: Leica RM2255 Microtome 
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2.6 Haematoxylin  
Reagents used in haematoxylin stainingprocedure are listed in the Table 2.2 below Mounted 
tissue sections were de-waxed in two changes of xylene each for 5 minutes and then hydrated 
to water in descending grades of ethanol starting from 100% followed by 95% and 70% for 
two minutes in each change. A fume cabinet was used to do the steps. Then tissue sections 
were rinsed well under running tap water for two minutes. 
 
 
 
Reagents 
 
 
Supplier 
Mayer’s Haematoxylin Australian Biostain P/L 
Ammonia solution BDH Chemicals Australia  
Dako mounting medium Dako 
 
Tissue sections were then placed in Mayer’s haematoxylin for five minutes to 
elaborate nuclei after which the sections were rinsed in running water to remove excess 
haematoxylin solution. Tissue sections were then placed in approximately 400ml of water 
mixed with 8 drops of ammonia solution for 30 seconds and later rinsed in running water. 
Tissue sections were checked under microscope to ensure nuclei were sufficiently stained. 
After that the sections were dehydrated in ascending grades of ethanol starting at 95% ethanol 
followed by two changes of 100% ethanol each for three minutes. Sections were cleared off 
ethanol using two changes of xylene for two minutes in each change. Tissue sections were 
then coverslipped with Dako cover glass 24 × 50 mm using Dako coverslipper. Slides stained 
for haematoxylin were used as the basis for selection of slides for immunostaining. 
  
Table 2.1: Reagents  
27 
 
 
2.7 Immunostaining 
Reagents used in immunostaining are listed in the Table 2.3. Heat-induced antigen retrieval 
solution was used as described in the specimen preparation and heat-induced antigen retrieval 
section. This was the EnVision FLEX solutions and target retrieval solutions intended for use 
in manual autoclave technique and the Dako PT Link equipment. All tissue specimens were 
treated with diluted 3% hydrogen peroxide (H2O2) for 20 minutes to block endogenous 
peroxidase activity. 
  
 
Reagents and chemicals Supplier 
EnVision FLEX Target Retrieval 
Solution - Low pH (50x)  
Dako Denmark  
30%  H2O2 diluted to 3% in de-
ionised Water (H2O)  
 
Merck Victoria  
EnVision FLEX Antibody diluent  
 
Dako Denmark  
EnVision Plus Anti-rabbit  
 
Dako Denmark  
TRIS Buffer  
 
May & Baker 
DAB 
 
Dako  
Anti-pSmad2/3 (Primary Ab) 
 
Santa Cruz 
 
 Buffers  
 
0.05M Trishydroxy-methyl-amino-methane-hydrochloric acid (TRIS-HCl) saline buffer at 
pH 7.6 was used for the rinsing step of immunohistochemistry. This was prepared using 
reagents listed in the Table 2.4 below.  
 
 
 
 
 
 
 
 
 
 
 
Table 2.2: Reagents  
28 
 
 
 
Reagents 
 
Supplier 
Trishydroxy-methyl-amino-methane 
(TRIS)  
MP Biochemicals, LLC  
Sodium chloride  Biolab (Aust) Limited  
EMSURE Hydrochloric acid 32% 
for analysis  
Merck KGaA Germany  
Tween 20  ICN Biochemicals, Inc.  
 
A stock solution of 0.5M Tris-HCl Saline Buffer pH 7.6 with Tween 20 was made 
from 60.56g of trishydroxy-methyl-amino-methane (TRIS) dissolved in 800ml de-ionised 
water, 90g of Sodium Chloride (NaCl) was added and dissolved in this solution. The pH of 
the solution was adjusted to 7.6 using concentrate hydrochloric acid (HCl) and 5ml of Tween 
20 was added to the solution. The solution was then transferred to a volumetric flask and 
made up to 1L with distilled water. The stock solution of 1L was then made up to 10L with 
distilled water to a working solution (in the Dako Autostainer container) of 0.05M Tris-HCl 
saline buffer pH 7.6.   
 
 Primary antibody  
 
Primary antibody used for the purpose of immunohistochemistry (IHC) is listed in the Table 
2.5 below.  
 
 
Antibody Type Clone Isotype Company/ 
supplier 
Concentrati
on (fresh) 
Anti-human 
pSmad2/3 
Polyclonal 
rabbit  
-  -  Santa Cruz  1/100 60min 
RT  
 
 Secondary link reagents and detection systems  
 
The EnVision+ system utilises a polymer-based immunohistochemical method with multiple 
antibodies on a polymer backbone and conjugated horseradish peroxidase (HRP) as depicted 
in the Figure 2.4 (134).  
 
Table 2.3: Buffers solution  
Table 2.4: Primary antibody  
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Reagents 
 
Supplier 
EnVision+ System-HRP Labelled 
Polymer Anti-rabbit  
 
Dako North America  
 
 
Figure 2.4: Labelled polymer horse-radish peroxidase system 
 
 Visualisation  
 
The chromogens used to enable visualisation in this study are listed in Table 2.7 below.  
 
 
 
 
Reagents Supplier 
Liquid 3,3’ Diaminobenzidine 
tetrahydrochloride (DAB) with substrate 
chromogen system  
 
Dako North America  
 
Table 2.5: Secondary link reagent and detection 
system   
Table 2.6: Visualisation reagents    
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2.8 Specimen preparation and heat-induced antigen retrieval  
 
Tissue samples underwent preparatory steps prior to immunostaining. Selected tissue sections 
were dried in an oven overnight at 37°C. Tissue samples were either treated for antigen 
retrieval using the Russell Hobbs pressure cooker or the Dako PT Link heat retrieval 
equipment. Methods for specimen preparation are described in the following section. 
 
  
2.9 Autoclave using Russell Hobbs pressure cooker  
 
Test slides that would undergo manual pre-treatment procedure using autoclave techniques 
were dewaxed and hydrated to water. Tissue samples that have been rinsed in running tap 
water for 2 minutes were then placed in a plastic container containing approximately 500mL 
of EnVision flex target retrieval solution low pH (Dako). Deionised water (500ml) was 
poured into the chamber of a Russell Hobbs pressure cooker as shown in the Figure 5, and the 
plastic container containing the test slides was placed in the pressure cooker. A plastic lid was 
loosely placed on the plastic container and the lid of the pressure cooker was secured. The 
pressure cooker was set to maximum heat for 6 minutes after which the dial was reduced to 
about 6.5 units for another 14 minutes just as the pressure cooker began to expel steam. The 
pressure cooker was then switched off and allowed to cool. The pressure cooker cover could 
only be removed once pressure inside has reduced. Test slides were then removed from the 
pressure cooker in the plastic container using a heat protective glove and allowed to cool 
below 35°C and then removed from the heat retrieval solution and rinsed in running tap water 
for 2 minutes. Test slides were then ready to be labelled and mounted onto the Dako 
Autostainer Plus as shown in Figure 2.7. 
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Figure 2.5: Russell Hobbs pressure cooker 
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2.10 Dako Pretreatment (PT) Link  
 
Test slides pre-treated using the Dako PT Link equipment (Figure 2.6) for heat-induced 
epitope retrieval were de-waxed and hydrated to water as per the autoclave technique. 
EnVision FLEX Target Retrieval Solution low pH (Catalogue no. K8005, Dako, Denmark) 
(30mL) was poured into a tank in the Dako PT Link and the solution was made up to 1500mL 
with deionised water to give a dilution factor of 1 in 50. The tank was then preheated to 
65°C. Labelled slides were then mounted onto a rack and placed inside the preheated tank. 
The Dako PT Link was programmed and the tank was heated to 97°C for 30 minutes after 
which it was cooled down back to 65°C. After the cycle has completed, rack containing slides 
were quickly and carefully removed from the tank and dipped into a PT Link rinse station 
that contained TRIS buffer pH 7.4 for 2 minutes as part of a quick-dip procedure. Test slides 
were then ready to be mounted onto the Dako Autostainer Plus as shown in Figure 2.7 
 
 
Figure 2.6: Dako PT Link 
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2.11 Immunostaining protocol  
Immunostaining protocols based on specifications of primary antibody as described above 
were programmed into the Dako Autostainer Plus software prior to immunostaining. Slide 
identification information was entered onto the ‘Slide Information’ window. Abbreviations 
for the primary antibody used along with its dilution factors and relevant optimised 
conditions (eg. use of PT Link, high or low pH pre-treatment condition and use of protein 
block) were keyed into data entry field labelled ‘Slide ID’. Participant’s unique identifying 
number, an indication of endobronchial biopsy (BB) followed by an alphabetical sequence 
indicating the tissue block it was cut from were keyed into data entry field labelled ‘Case#’. 
The Respiratory Research Group was labelled as the Doctor for all cases to allow data 
recovery in the future. The figure ‘1’ was keyed into data entry field labelled ‘#Slides’ 
indicating data entered were for one prepared slide. The entries were checked once again and 
entries were confirmed by clicking the button ‘Finish Entry’ to give an output programme.  
 
 
Figure 2.7: Dako Autostainer Plus 
 
Immunostaining protocols were programed into the Dako Autostainer Plus software. 
Treatment with endogenous enzyme blocks, primary antibodies, secondary link reagents and 
substrate as shown in table 6, as well as rinsing steps were entered into the program. 
Adhesive slide labels were then printed from the Dako Seymour Glass Label Printer. 
Prepared slides were then labelled prior to specimen preparation methods. 
34 
 
At the start of immunostaining protocols utilising the autostainer (and after heat 
retrieval), tissue samples were pre-rinsed with TRIS-HCl saline buffer. The visualisation 
system utilised in all immunostaining protocols in this study was horseradish peroxidase 
(HRP) using the Dako Envision+ system. As such, all slides were treated with 3% H2O2 for 
20 minutes to block endogenous peroxidase activity in tissue samples and eliminate potential 
background staining. Tissue samples were again rinsed with TRIS-HCl saline buffer.  
Tissue samples were then treated with specified primary antibody at optimised 
dilution factor (1/100) and incubated in the humidified staining chamber at appropriate 
incubation time i.e. 60 minutes (room temperature were set at 22°C and humidified 
conditions were created by dampening paper towels placed at the bottom of the sink). 
Following incubation with primary antibodies, slides were rinsed three times with TRIS-HCl 
saline buffer. Secondary link reagent (see table 5) corresponding to the isotype of the primary 
antibody was then applied to tissue samples for 30 minutes. Slides were then rinsed three 
times with TRIS-HCl saline buffer. Substrate chromogen (DAB+ see table 6) was applied to 
tissue samples as the visualisation system for 10 minutes. Test sections were once again 
washed with TRIS-HCl saline buffer and subsequently washed with deionised water.  
Test slides were then removed from the autostainer and rinsed in running water, then 
counterstained with Mayers haematoxylin for 5 minutes to elaborate nuclei as per H & E 
staining procedure as previously described. Tissue sections were checked under microscope 
to ensure nuclei were sufficiently stained. Tissue sections were then dehydrated, cleared and 
mounted in Dako mounting media (table 2). Test slides were then dried over a hot plate at 
60°C overnight in order to dry mounting medium. Date of run was recorded on each 
completed test slide at the end of a run.  
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Figure 2.8: Dako Coverslipper 
 
2.12 Controls  
Tissue controls were selected from material known to possess the antigen of interest and used 
to validate each run of the immunostaining. The same control material was also used to 
validate the staining of tissue as a result of using the two different heat retrieval methods 
(autoclave vs PT link device) that came about as result of  the purchase of new equipment 
(PT link device).  
Isotype negative controls were utilised as reagent controls i.e. for each biopsy a serial 
section of that slide had isotype matched primary antibody applied to replace the pSmad2/3 
primary. All the negative controls that were conducted were found to be stained negative 
indicating that the immunochemistry method did not label non-specific antigens associated 
with either the Fc region of the primary antibodies or the secondary link reagents. Reagents 
used in this study were controlled by utilising standard diluents and appropriate reagents as 
well as documenting each immunostaining run that was conducted to ensure quality control.  
Humidity in the autostainer was maintained by laying paper towels immersed in 
deionised water and room temperature was based on building-wide temperature of 22℃.  
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2.13 Histological and immunohistochemical analysis  
Computer-assisted image analysis was conducted using Leica DM2500 microscope (Leica 
Microsystems, Germany) and Leica camera (Supplier- Leica Bioscience, Product code- 
DFC495) (Figure 2.9) that was linked to an image analysis software, Image Pro Plus Version 
7.0 (Media Cybernetics, US). 
 
 
Figure 2.9: Biopsy image analysis equipment with Leica DM2500 microscope and digital 
camera  
 
On each slide, two biopsy sections were fixed for analysis as shown by drawing circles 
around them in Figure 2.10. First, as many pictures as possible were taken from both of the 
tissue sections from the area of interest (for this study it was mainly epithelium, Rbm, and 
lamina propria) for each slide. Only subjects with sufficient amounts of tissue were analysed. 
Sections were photographed if they had intact epithelium and LP, with no holes or tissue 
damage. Most subjects had one section suitable for imaging; where two or more sections 
from a single subject were suitable, all images were grouped together and treated as if from 
the same section. Once photographed, five images were randomly chosen from each subjects’ 
‘pool’ of images and used for measurements. The number of epithelial cells, cells in the Rbm, 
blood vessels in the Rbm and LP were stained by pSmad2/3 was counted using the automated 
software (Image Pro Plus) (Figure 2.9). Cells and vessels were classified by the investigator, 
based on their morphology. 
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Figure 2.10: Showing two biopsy sections fixed on a pSmad slide with black circles around them, 
arrows indicate the location of the biopsies. 
 
The positively stained blood vessels up to 150μ deep into lamina propria (Figure 2.11) 
were measured. These numbers were presented as cells and vessels per unit length of Rbm 
and per unit area of LP. The percentage of vessels in the Rbm and LP stained for pSmad2/3 
was calculated by dividing the number of vessels stained for pSmad2/3 by the total number of 
vessels. All slides were coded and randomised by an independent person and then counted in 
a single batch by this investigator who was blinded to subject and diagnosis. For quality 
assurance and validity purposes, randomly selected slides were measured and matched with 
results from this investigator by another researcher who is very experienced at image 
analysis.     
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Figure 2.11: Showing a biopsy image under the microscope for analysis (Magnifications X40) 
 
  
Epithelium 
Rbm 
̴150μ deep into LP 
Basal epithelial cells 
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Chapter 3 - Results 
 
Transforming growth factor beta (TGFβ) is one of the most important tissue and cell 
regulators (52, 82, 92, 132). Studies on lungs have shown that TGFβ can induce pathological 
changes through Smad protein activation (68, 81, 87, 135). TGFβ activity is shown to be 
increased among smokers, particularly with chronic obstructive pulmonary disease (COPD) 
group (118). A cross-sectional study was designed to investigate the phosphorylated Smad2/3 
(pSmad2/3) pathway between smokers, smokers with COPD, ex-smokers with COPD and 
non-smokers with healthy lungs.  
A longitudinal study was also designed, using the same cohort as the cross-sectional study, to 
study the effects of inhaled corticosteroids (ICS) on COPD airways. ICS has been widely 
used for the treatment of COPD for the last two decades (136). A study on bronchial vascular 
remodelling in COPD patients treated with steroids showed significant reduction in positive 
TGFβ expression compared to non-treated COPD group (137). This longitudinal study was 
designed to investigate the positive immunostaining of pSmad2/3 on vascular remodelling for 
the COPD group who were on ICS and compared with the placebo group.  
3.1 Subjects demographics  
For the cross-sectional study, 57 people were recruited, 15 were healthy non-smokers (NC), 
13 were smokers with normal lung function (NLFS), 15 were current-smokers with COPD 
(COPD-CS), and 14 were ex-smokers with COPD (COPD-ES). Due to insufficient tissues 
from the samples from 3 of the control subjects, 12 participants’ tissues were used for study. 
12 of COPD ex-smokers subjects’ samples were used for analysis as the other 2 did not have 
sufficient tissues on their samples.  
For the longitudinal study, 12 COPD subjects from the same cohort had sufficient tissue to 
perform the analysis of the effects of ICS. Nine of these subjects were treated with 
fluticasone propionate (0.5mg) twice daily for six months and three received a placebo.  
The subjects’ demographics can be seen in table 3.1 and 3.2. There were no statistically 
significant differences in the male to female ratios across the groups (p>0.05). People with 
COPD smoked significantly more than normal lung function smokers (p<0.05); however, 
given the difference in age between the groups (p<0.05) this is not unexpected as COPD 
groups were older and they had more time to smoke. People with COPD had significantly 
lower lung function than non-smokers and smokers with normal lung function (p<0.05). 
Subjects that are used for the longitudinal study did not have any statistical significant 
difference for lung function (p>0.05), smoking pack-years (p>0.05), nor the age (p>0.05) 
(table 3.2).   
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Table 3.1: Demographics for cross-sectional study  
Groups Normal 
Controls 
(n=15) 
Smokers 
(n=13) 
COPD 
Smokers 
(n=15) 
 
COPD Ex-
smokers 
(n=14) 
p value 
Age (years) 
  
54 (20-68) 46 (30-66) 60 (48-69) 62 (53-69) <0.05 
Male/Female 
 
7/8 9/4 9/6 9/5 >0.05 
Smoking history 
(Pack-years) 
0 32 (10-57) 44 (18-82) 66 (18-150) 0.02* 
0.01
+ 
FEV1% predicted 
(Post-BD) 
119 (114-124) 99 (78-125) 79 (55-100) 80 (55-105) <0.05 
FEV1/FVC% 
(Post-BD) 
82 (71-88) 77 (70-96) 59 (47-68) 57 (38-68) <0.05 
 
Demographics of the study population.  
Post-BD= Post- bronchodilator response after 400μg of salbutamol. FEV1= forced expiratory volume 
in 1 second, FVC= forced vital capacity. Smoking history in pack-years was calculated by multiplying 
the number of packs of cigarettes smoked per day by the number of years the person has smoked.  
Data expressed as median (range). 
*COPD current-smokers vs normal lung function smokers.  
+
COPD ex-smokers vs normal lung function smokers.  
 
Table 3.2: Demographics for longitudinal study  
 
Groups Placebo 
(n=3) 
Steroid 
 (n=9) 
p value  
Age (years) 61 (56-66) 60 (48-69) 0.73 
Male/Female 2/1 6/3 1.00 
Smoking history 
(Pack-years) 
59 (51-71) 46 (18-82) 0.23 
FEV1% predicted 
(Post-BD) 
 
68 (55-76) 75 (55-105) 0.28  
FEV1/FVC% 
(Post-BD) 
59 (38-63)  56 (47-65) 0.86 
 
Demographics of the study population.  
Post-BD= Post- bronchodilator response after 400μg of salbutamol. FEV1= forced expiratory volume 
in 1 second, FVC= forced vital capacity. Smoking history in pack-years was calculated by multiplying 
the number of packs of cigarettes smoked per day by the number of years the person has smoked.  
Data expressed as median (range). 
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3.2 Cross-sectional study 
 
General morphology 
 
In COPD structural changes are observed in airways, such as goblet cell hyperplasia, mucus 
hypersecretion (67, 138), infiltration of numerous cells, and remodelling of the extracellular 
matrix (39, 139).These changes worsen as the disease progresses and are not reversed by 
smoking cessation (54).  
 
Normal non-smokers had pseudostratified epithelial layer, with all epithelial cells adhered to 
each other in one layer and the epithelium was not fragmented. This is demonstrated in figure 
3.1A. The epithelium, shown by the blue line in 3.1A, covered the most superficial part of 
mucosa and the yellow line shows what were considered basal epithelial cells in this study. 
The epithelial layer was attached to the reticular basement membrane (Rbm) (the orange 
line), which was a smooth, unbroken structure in normal non-smokers. The Rbm lies beneath 
the epithelium and separates it from the lamina propria (LP). The LP, shown by green line in 
3.1A was made up of loose connective tissue and contained cells and blood vessels. Smokers 
with normal lung function had similar structure, however, there were occasionally gaps 
between epithelial cells (shown by arrows), and the overall structure began inclining towards 
stratified morphology, as seen in 3.1B. COPD current-smokers had more fragmented 
epithelium, losing their cuboidal morphology and at some points becoming almost detached 
from the basement membrane, shown by arrows in figure 3.1C. Across all the groups, there 
were large ranges of thickness of epithelium. An example of this can be seen in figure 3.2 for 
the COPD current-smokers group. COPD current-smokers particularly appeared to segregate 
into two sub-groups, one with epithelial hyperplasia (3.2A) and one that demonstrated normal 
epithelial thickness (3.2B), this was statistically significant (p<0.01). COPD ex-smokers also 
had epithelium which had lost their cuboidal morphology and appear more ragged and 
disorganised, as shown by arrows in 3.1D.  
 
The reticular basement membranes (Rbm) in normal non-smokers were narrow, smooth and 
consistent, underlining the epithelium distinctly as shown by orange line in 3.1A. Smokers 
with normal lung function had similar Rbm structure lining the epithelium (arrowheads in 
3.1B). For COPD current-smokers, the Rbm seemed thicker and fragmented, shown by 
arrowheads, with cells present in the clefts, as shown by the red circles in 3.1C. COPD ex-
smokers also seemed to have thickened and fragmented Rbms, indicated by arrowheads, and 
exhibit cellularity (red circle in 3.1D). COPD current-smokers also had blood vessels in the 
Rbm as shown in figure 3.3B by green arrows.  
 
The structure of the lamina propria (LP) appeared to be similar across all the groups (figure 
3.1), however, COPD current-smokers seemed to have more blood vessels than non-smokers, 
which can be in seen in figure 3.3, where the LP vessels are indicated by red circles, and also 
shown later on figure 3.8, however, this was not quantitatively measured. 
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Figure 3.1 Microphotograph from subjects from each group in the study showing 
biopsies stained with haematoxylin and an antibody directed against phosphorylated 
Smad2/3 (pSmad2/3).   
Biopsies from patients from each group, panel A shows normal non-smokers (NC), panel B shows 
smokers with normal lung function (NLFS), panel C shows COPD current-smokers and panel D 
shows COPD ex-smokers. Each picture is a general representation of the entire group, showing 
pSmad2/3 staining of the epithelium and sub-epithelial layers. On panel A, the blue line indicates the 
epithelium area, the yellow line shows the basal epithelial cells, which were measured 15μm from the 
basement membrane towards the epithelium, the orange line indicates the reticular basement 
membrane (Rbm) below the epithelium, and the green line indicates the lamina propria (LP) 
underneath the basement membrane, where the blood vessels were measured to a depth of 150μm 
from the internal (deep) border of the Rbm. In panel B, the white arrows show the gaps between 
epithelial cells and the black arrowheads show the Rbm lining the epithelium. In panel C, the white 
arrows show how epithelial cells losing their attachment to the basement membrane in COPD current-
smoker subject and the black arrowheads and red circles show clefts and cells in the clefts 
(A) (B) 
(C) (D) 
50 μm 
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respectively. In panel D, the white arrows show the distorted epithelium and red circle shows cells in 
the Rbm. Original magnification X 40. Scale = 50μm.       
 
 
 
 
 
Figure 3.2: Variability in epithelium thickness in COPD current-smokers group.  
The upper panel (A) shows thickened and disorganised epithelium as shown by orange arrows, 
whereas the lower panel (B) shows thin epithelium as indicated by orange arrow. Original 
magnification X 40. Scale = 50μm.        
(A) 
50 μm 
(B) 
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Figure 3.3: Variability in blood vessels in the COPD current-smokers.  
The upper panel (A) shows normal non-smokers, with few blood vessels in the LP as shown by red 
circles, whereas the lower panel (B) shows a number of blood vessels positively immunostained for 
pSmad2/3in the Rbm and LP of COPD current-smokers as shown by green arrows and red circles 
respectively. Original magnification X 40. Scale = 50μm.        
(A) 
(B) 
50 μm 
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In order to determine the phosphorylation of Smad2/3 in these morphological changes, 
different areas of the tissues for 4 different groups were analysed.  
 
3.3 Epithelial cells  
 
In COPD, the epithelium undergoes numerous changes including hyperplasia and goblet cell 
hypersecretion (139, 140). Transforming growth factor beta (TGFβ), being a multifunctional 
cytokine, induces structural, cellular, and inflammatory changes in the lungs (92, 141). Smad 
is the predominant pathway through which TGFβ regulates its function, using phosphorylated 
(activated) Smads (pSmads) (132, 133). Hence, the aim was to investigate whether 
pSmad2/3, the most commonly seen pSmads complex (83, 88, 142), is active in the 
epithelium of the COPD. 
 
In order to study the pSmad2/3 immunostaining, the epithelial cells stained positive for 
pSmad2/3 for the four groups were counted. There were no statistically significant 
differences for pSmad2/3 staining in the epithelium across the four groups (p>0.05), and none 
of the groups were significantly different from controls (p>0.05) as shown in Figure 3.4A. 
 
However, there were statistically significant differences among the four groups for 
percentage epithelium (p=0.01), as shown in figure 3.4B. COPD current-smokers had higher 
percentage of epithelial cells stained for pSmad2/3 than controls (p=0.04). COPD ex-smoker 
also had higher percentage of epithelial cells than controls (p=0.01). Normal lung function 
smokers had the same percentage of positive pSmad2/3 epithelial cells as controls (p>0.05) 
(figure 3.4B).   
 
 
Table 3.3: The number of epithelial cells in total and positively stained for pSmad2/3 (raw 
data in appendix 1) 
 
 Normal 
Controls 
(n=12) 
Smokers 
(n=13) 
COPD 
Smokers 
(n=15) 
 
COPD  
Ex-smokers 
(n=12) 
p value 
pSmad2/3 cells 0.19/μm 
(±0.08) 
 
0.20/μm 
(±0.11) 
0.19/μm 
(±0.10) 
0.21/μm 
(±0.07) 
>0.05
+ 
>0.05
++ 
Total cells  0.21/μm 
(±0.09) 
0.22/μm 
(±0.11) 
0.19/μm 
(±0.10) 
0.22/μm 
(±0.08) 
>0.05
+ 
>0.05
++ 
 
+ 
represents p value across all 4 groups, 
++ 
represents p value for all 3 groups against control. 
The data are presented as mean (standard deviation). The mean data are represented per unit 
of the reticular basement membrane. 
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Figure 3.4: (A) Epithelial cells per μm of Rbm stained for pSmad2/3; the epithelial cells were 
compared in healthy non-smokers (NC), normal lung function smokers (NLFS), current-smokers with 
COPD (COPD-CS), and ex-smokers with COPD (COPD-ES). (B) The percentages of epithelial cells 
stained for pSmad2/3; the percentages were compared in healthy non-smokers (NC), normal lung 
function smokers (NLFS), current-smokers with COPD (COPD-CS), and ex-smokers with COPD 
(COPD-ES). The lines indicate the mean values for each group. (* indicates a p value <0.05, ** 
indicates a p value <0.01 and *** indicates a p value <0.001). For each subject, 5 images were 
obtained and the numbers of positively stained cells in the epithelium were counted for each picture. 
Then, the numbers of positive cells per unit for the same subject were calculated by dividing the total 
number of cells by the total length of the basement membrane. Each point on the graph shows the data 
for a single subject.   
* 
* 
(A) 
(B) 
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3.4 Basal epithelial cells  
 
The proportion of epithelial cells showed a significant increase for the COPD groups and it is 
possible that the airway basal cells are more active than the apical cells as airway basal cells 
are central to the pathogenesis of smoking-associated lung diseases (143). This study 
investigated the pSmad2/3 staining in the basal epithelial cells between the 4 groups, so as to 
study the migratory characteristics of the basal epithelial cells. These cells are thought to 
undergo epithelial to mesenchymal transition (EMT) and migrate through the basement 
membrane, as they are closest to the membrane and also the site of the earliest abnormalities 
in smokers’ lungs (143). Since no basal cell markers were used to distinguish them from the 
other non-stem cells, in this study the basal epithelial cells are defined as any epithelial cells 
within 15μm of the basement membrane.    
 
In order to determine the pSmad2/3 staining for the basal epithelium, the basal epithelial cells 
stained positive were counted for the subjects. There were no statistically significant 
differences for pSmad2/3 staining in the basal epithelial cells across the four groups (p>0.05), 
and none of the groups were significantly different from controls (p>0.05) as shown in Figure 
3.5. 
 
 
Figure 3.5: Basal epithelial cells per μm of Rbm stained for pSmad2/3; the basal epithelial cells were 
compared in healthy non-smokers (NC), normal lung function smokers (NLFS), current-smokers with 
COPD (COPD-CS), and ex-smokers with COPD (COPD-ES). The lines indicate the mean values for 
each group. (* indicates a p value <0.05, ** indicates a p value <0.01 and *** indicates a p value 
<0.001). For each subject, 5 images were obtained and the numbers of positively stained basal 
epithelial cells (15μm from the basement membrane towards the epithelium) were counted for each 
picture. Then, the numbers of positive cells per unit for the same subject were calculated by dividing 
the total number of cells by the total length of the basement membrane. Each point on the graph 
shows the data for a single subject.   
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3.5 Rbm cells  
 
COPD airways have been shown to have cells present in the reticular basement 
membrane (Rbm) (29). These cells have been shown to be positive for EMT biomarkers that 
are broadly referenced in EMT studies, matrix metalloproteinase-9 (MMP-9), the fibroblast 
protein (S100A4) and mesenchymal marker, vimentin (29, 67, 144). To rule out the 
possibility of these cells being inflammatory cells, the biopsies were stained for neutrophil 
marker, macrophage (CD68) marker, and very few neutrophils and macrophages were found 
in the Rbm (29). Therefore, the question arises whether pSmad2/3 are up-regulated in the 
Rbm cells to drive TGFβ pathway in the COPD groups. This study investigated the Rbm cells 
showed positive pSmad2/3 staining for the 4 different groups.  
In order to measure the pSmad2/3 staining for the Rbm cells, the numbers of positive 
pSmad2/3 cells in the Rbm were counted. There were statistically significant differences for 
pSmad2/3 staining in the Rbm cells across the four groups (p=0.01). COPD ex-smokers 
group was significantly different from controls (p=0.01) for pSmad2/3 staining in the Rbm 
cells, as shown in Figure 3.6. Neither COPD current-smokers nor normal lung function 
smokers were significantly different from controls (p>0.05).  
 
 
Figure 3.6: Rbm cells per mm of Rbm stained for pSmad2/3; the Rbm cells are compared in healthy 
non-smokers (NC), normal lung function smokers (NLFS), current-smokers with COPD (COPD-CS), 
and ex-smokers with COPD (COPD-ES). The lines indicate the mean values for each group (* 
indicates a p value <0.05, ** indicates a p  value <0.01 and *** indicates a p value <0.001) For each 
subject, 5 images were obtained and the numbers of positively stained Rbm cells were counted for 
each picture. Then, the numbers of positive cells per unit for the same subject were calculated by 
dividing the total number of cells by the total length of the basement membrane. Each point on the 
graph shows the data for a single subject.    
* 
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3.6 Rbm vessels  
 
Angiogenesis is one of the hallmarks of type 3 EMT which is associated with cancer 
progression and other malignancies (60).  Hypervascularity was evident in the Rbm during 
airway remodelling in smokers with COPD, and TGFβ immunostaining was increased in 
these blood vessels (118). This study investigated the blood vessels in the Rbm to quantify 
the pSmad2/3 staining in the 4 groups in order to study which pathway TGFβ is acting 
through.   
 
In order to investigate the pSmad2/3 positive blood vessels, the positive blood vessels were 
counted in the basement membrane and compared between the groups. There were 
statistically significant differences for pSmad2/3 staining in the Rbm blood vessels across the 
four groups (p=0.001). COPD current-smokers group was significantly different from 
controls (p=0.01) for pSmad2/3 staining in the Rbm vessels, as shown in figure 3.7A. 
Furthermore, COPD current-smokers group was also significantly different from normal lung 
function smokers (p=0.001) and from COPD ex-smokers (p=0.03), as shown in figure 3.7A. 
Neither normal lung function smokers nor COPD ex-smokers were significantly different 
from controls (p>0.05).  
 
There were statistically significant differences among the four groups for percentage 
pSmad2/3 staining of Rbm vessels (p<0.01), as shown in figure 3.7B. COPD current-smokers 
had higher percentage of Rbm vessels stained for pSmad2/3 than controls (p=0.002). 
Moreover, COPD current-smokers group was also significantly different from normal lung 
function smokers (p<0.01). Neither COPD ex-smokers nor normal lung function smokers 
were significantly different from controls (p>0.05) (figure 3.7B).   
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Figure 3.7: (A) Rbm vessels per mm of Rbm stained for pSmad2/3; (B) the percentage of Rbm 
vessels, the Rbm vessels are compared in healthy non-smokers (NC), normal lung function smokers 
(NLFS), current-smokers with COPD (COPD-CS), and ex-smokers with COPD (COPD-ES). The 
lines indicate the mean values for each group (* indicates a p value <0.05, ** indicates a p value 
<0.01 and *** indicates a p value <0.001). For each subject, 5 images were obtained and the numbers 
of positively stained Rbm vessels were counted for each picture. Then, the numbers of positive 
vessels per unit for the same subject were calculated by dividing the total number of vessels by the 
total length of the basement membrane. Each point on the graph shows the data for a single subject.   
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3.7 LP vessels  
Bronchial vascular remodelling has also been shown to occur in lamina propria (LP) (65, 
137). TGFβ immunostaining was increased in these blood vessels (118) and therefore this 
study investigated the blood vessels in the LP to quantify the pSmad2/3 staining in the 4 
groups in order to study which pathway TGFβ is acting through in LP vessels.   
 
In order to investigate the pSmad2/3 positive blood vessels in LP, the positive blood vessels 
150μm deep into the LP were counted and compared between the groups. There were 
statistically significant differences for pSmad2/3 staining in the LP blood vessels across the 
four groups (p=0.01). COPD current-smokers group was significantly different from controls 
(p=0.01) for pSmad2/3 staining in the LP vessels, as shown in figure 3.8A. Moreover, COPD 
current-smokers group was also significantly different from normal lung function smokers 
(p=0.04) and from COPD ex-smokers (p=0.03), as shown in figure 3.8A. Neither normal lung 
function smokers nor COPD ex-smokers were significantly different from controls (p>0.05).  
 
There were statistically significant differences among the four groups for percentage 
pSmad2/3 staining of LP vessels (p<0.01), as shown in figure 3.8B. COPD current-smokers 
had higher percentage of LP vessels stained for pSmad2/3 than controls (p<0.01). COPD ex-
smokers also had higher percentage of LP vessels stained for pSmad2/3 than controls 
(p=0.01). Normal lung function smokers had the same percentage of pSmad2/3 staining of LP 
vessels as controls (p>0.05) (figure 3.8B).   
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Figure 3.8: (A) LP vessels per mm² stained for pSmad2/3; (B) the percentage of LP vessels, the LP 
vessels are compared in healthy non-smokers (NC), normal lung function smokers (NLFS), current-
smokers with COPD (COPD-CS), and ex-smokers with COPD (COPD-ES). The lines indicate the 
mean values for each group (* indicates a p value <0.05, ** indicates a p value <0.01 and *** 
indicates a p value <0.001). For each subject, 5 images were obtained and the numbers of positively 
stained LP vessels were counted for each picture. Then, the numbers of positive LP vessels (150μ 
deep into lamina propria) per unit for the same subject were calculated by dividing the total number of 
vessels by the total area of the lamina propria. Each point on the graph shows the data for a single 
subject.   
*** 
* 
* 
* * 
(A) 
(B) 
53 
 
3.8 Inhaled corticosteroid effects on vascular remodelling in COPD airways: A 
longitudinal study  
 
The use of inhaled corticosteroids (ICS) has been shown to be beneficial in COPD, including 
reducing the rate of exacerbations in COPD, reducing the rate of decline in lung function, and 
improving the quality of life (145, 146). The increased angiogenic activity in the Rbm and LP 
has been reported to respond to treatment with ICS (147, 148). Therefore, this study 
investigated the effects of ICS on pSmad2/3 staining for the COPD blood vessels in order to 
study whether the ICS is working through pSmad2/3 proteins.  
 
To assess the ICS effects on pSmad2/3 staining in the blood vessels, the number of vessels 
stained positive for pSmad2/3 in the Rbm and LP were counted from the COPD cohorts 
before and after 6 months of ICS treatment (0.5mg fluticasone propionate twice daily) and 
compared to the placebo group. There were no statistically significant differences in 
pSmad2/3 staining, neither in Rbm nor LP vessels for the treatment arm as compared to the 
placebo arm (p>0.05) (figure 3.9).      
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Figure 3.9: (A) Rbm vessels per mm stained for pSmad2/3; (B) LP vessels per mm
2
 stained for 
pSmad2/3, compared between the placebo and treatment groups. The lines indicate the mean values 
for each group. For each subject, 5 images were obtained and the numbers of positively stained 
vessels were counted for each picture. Then, the numbers of positive vessels per unit for the same 
subject were calculated by dividing the total number of vessels by the total length of Rbm for Rbm 
vessels and total area of the LP for LP vessels. Each point on the graph shows the data for a single 
subject.    
(A) 
(B) 
55 
 
Chapter 4 - Discussion 
 
 
4.1 General overview  
 
This study has revealed novel aspects of airway remodelling in the airways in COPD patients 
with or without smoking effects. The main results can be summarised as follows: 
 
1) The epithelium in patients with COPD had more phosphorylated Smad2/3 (pSmad2/3) 
immunostaining than healthy non-smokers, regardless of smoking status.  
2) The basal epithelium in patients with COPD and smokers with healthy lungs were not 
different in pSmad2/3 immunostaining than non-smokers.  
3) The reticular basement membrane (Rbm) appeared to be morphologically different in 
the COPD groups. It seemed thicker, fragmented and cells were present in the clefts. 
COPD ex-smokers had significantly more Rbm cells showing pSmad2/3 
immunostaining than healthy non-smokers. 
4) There were more pSmad2/3 immunostaining in the blood vessels in the Rbm for 
current-smokers with COPD than the non-smokers with healthy lungs. However, this 
was not observed for smokers with normal lung function or ex-smokers with COPD.  
5) There were more pSmad2/3 immunostaining in the blood vessels in the lamina propria 
(LP) for COPD groups than in non-smokers with healthy lungs, but not in smokers 
with normal lung function. 
6) Inhaled corticosteroids had no effects on pSmad2/3 immunostaining on blood vessels 
in COPD airways.   
 
 
4.2 Epithelial layer 
 
The current study showed increased pSmad2/3 immunostaining in the epithelial cells of 
COPD patients, both for current and ex-smokers compared to healthy subjects who were non-
smokers in vivo. However, the basal epithelium did not show any significant difference for 
pSmad2/3 immunostaining for the COPD and smokers groups.  
 
In the airways of smokers and patients with COPD, epithelial-mesenchymal transition (EMT) 
was shown in bronchial epithelial cells and it was also found that cigarette smoke extract 
promoted the phosphorylation of Smad3 in the bronchial epithelial cells (67). However, their 
study was focused on molecular methods and in vitro models. They measured phosphorylated 
Smad3 by protein array technology (67). Moreover, another in vitro study demonstrated that 
Smad2/3 signaling pathways that were activated by TGFβ caused EMT-related changes in 
pulmonary epithelial cells (142). Based on my findings and these findings, it may suggest that 
more Smad2/3 proteins are phosphorylated in the COPD airways and cigarette smoking may 
play a role in this, maybe by activating the TGFβ pathway, activating its downstream 
signaling Smad2/3 cascade through phosphorylation to promote COPD airway epithelium 
changes. This may contribute to the disease and possibly activate the transition of epithelial 
cells to cause them to lose their cuboidal morphology and become more mesenchymal.   
 
However, there were limitations in this study that need to be considered. EMT markers that 
are broadly referenced in EMT studies such as the cytoskeletal proteins α-smooth muscle 
actin (α-SMA), vimentin (mesenchymal markers) (81) and epithelial E-cadherin, cytokeratin 
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(epithelial markers) (60) were not analysed to quantitate EMT in these biopsies. Additionally, 
for the basal epithelial cells that were counted in this study, the basal cell markers including 
Pdpn, Hopx and AGER (149, 150) could have been analysed to investigate the 
phosphorylation of the Smad2/3 in the progenitor cell population of the epithelium.                  
    
Despite the fact that airway basal cells were not properly identified, the current study 
revealed overall an increased proportion of epithelial cells showing pSmad2/3 
immunostaining in patients with COPD. The pSmad2/3 proteins are possibly involved in the 
pathology of this disease, particularly in those who are smokers. Cigarette smoke may cause 
phosphorylation of Smad2/3 and other transcription factors, which may activate transcription 
of genes that result in pathological changes in the epithelium, which may include EMT. 
However, the precise role of cigarette smoking and pSmad2/3 in COPD still requires further 
investigation. The current study measured the positive staining of activated or phosphorylated 
Smad2/3 proteins in the epithelial cells, regardless of these proteins’ location. Future study 
can focus on the location of these proteins in the cells, as this can potentially reveal more 
about its activity, as the Smad proteins are known to accumulate in the nucleus in response to 
TGFβ in order to have an effect (133). When Smads are phosphorylated after their receptor is 
activated by TGFβ, their affinity for cytoplasmic anchors are reduced and affinity for nuclear 
factors are increased, resulting in nuclear accumulation (141). 
 
Additionally, it is also important to study the non-phosphorylated Smads as well as other 
Smads that are also involved in this pathway (133) and their involvement in COPD airways. 
In particular, inhibitory Smads 6 & 7 would be good subjects for study. If there is an up-
regulation of Smads 6 & 7 concurrent with activation of Smad 2 & 3, then the Smad 2 & 3 
may not be able to activate target gene transcription (Figure 4.1).  
 
Figure 4.1: The TGFβ signaling pathway through Smads (125) 
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In this study, no differences were found in the total number of epithelial cells between the 
groups. The thickness of epithelium varied within the groups. Even non-smokers had a large 
range of epithelium thickness, even though the epithelium was compact, unlike the COPD 
and smokers groups. Epithelium is the first anatomical barrier that is exposed to the noxious 
particles of cigarette smoke and is involved in initiating the airway remodelling process 
through the release of inflammatory mediators (138), extracellular mediators including 
transforming growth factor beta (TGFβ) (84), and other fibrogenic mediators (151). Cigarette 
smoking is one of the key factors that lead to this airway remodelling manifested by 
metaplasia of the epithelium (152). The finding in this current study is contradictory to 
previous findings which show thickening of the epithelium (1, 43, 151). However, there can 
be a number of reasons for this. There just may be natural variation between subjects or it 
may be that non-smoking subjects were exposed to second hand smoke, as this study did not 
take that into consideration. COPD groups were significantly different for their smoking 
history from smokers with normal lung function. Therefore, the smokers with high and low 
pack years may contribute to the differences in the epithelial cells variation. Studies about 
pathological characteristics of the airways in COPD mention in addition to increased 
thickness of the wall (67, 153), epithelial goblet cell hyperplasia, squamous metaplasia and 
epithelial-mesenchymal transition (EMT) (41, 152). 
 
Camara et al showed that upon stimulation of TGFβ, primary human bronchial epithelial 
cells undergo EMT through primarily Smad2/3 dependent mechanism (68). Milara et al also 
showed human bronchial epithelial cells undergo EMT after cigarette smoke extract exposure 
through the release of TGFβ and phosphorylation of Smad3 (67). In line with these results, 
this current study also shows that Smad2/3 is more phosphorylated in the epithelium of 
COPD than non-smokers, possibly driving the TGFβ pathway.. TGFβ has been considered to 
be a key factor in the induction of EMT in pulmonary epithelium (142), and Smad 
transcription factors are well known mediators of TGFβ signaling (133). Kolosova et al 
showed that within minutes of TGFβ1 exposure Smad2 and Smad3 were activated as was 
evidenced by their phosphorylation in pulmonary epithelial cells (142). They also showed 
that collagen I gene up-regulation were dependent on both Smads, Smad2 and Smad3 (142). 
The tissue deposition of type I collagen was caused by an increase in the rate of transcription, 
resulting in fibrotic EMT (154). The involvement of Smad3 in EMT causing fibrosis has been 
demonstrated in vivo and in vitro in other tissues such as the eye and kidney (155, 156), as 
well as the lungs (142). It is still not clear whether both Smad2 and Smad3 are responsible for 
TGFβ1 induced EMT. However, they may be involved in increased deposition of 
extracellular matrix (ECM) proteins in the sub-epithelial layer.   
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4.3 Sub-epithelial layer 
The first sub-epithelial layer, the reticular basement membrane (Rbm) was morphologically 
different for the COPD groups from non-smokers and from smokers with healthy lungs. The 
Rbm seemed thicker, fragmented and cells were present in the clefts in patients with COPD. 
Liesker et al showed that Rbm thickening occurs in COPD (157). However, others have not 
found this difference (158, 159). Chanez et al showed that a subgroup of COPD with 
eosinophilic inflammation of airways had thicker Rbm than others (159), suggesting that 
Rbm thickening is an asthma phenotype (159). The discords about the Rbm thickness in 
COPD still remain to be elucidated. It can be proposed that the Rbm splitting could be the 
result of changes in ECM, new layers being formed by the epithelial cells, or may be 
degradation of the Rbm by proteolytic enzymes, due to stress or smoking. The major 
limitation in this current study should be highlighted that the thickness or the area of the Rbm 
was not measured or analysed and can be a potential area to be studied in future. Perhaps, the 
thickness of Rbm may be related to the cellularity that is seen in COPD patients.    
Interestingly, this current study showed that the ex-smokers with COPD had a significant 
increase in pSmad2/3 immunostaining in the Rbm cells from non-smokers, as to however 
current-smokers with COPD were not significantly different from non-smokers. Previous 
works have shown that Rbm cells stain positive for the proteolytic enzyme, matrix 
metalloproteinase-9 (MMP-9), the early fibroblast transition marker, S100A4, vimentin, and 
other established EMT markers (29). A comparative analysis demonstrated that there were 
only very few neutrophils and macrophages, and concluded the majority of the cells in the 
Rbm were not inflammatory cells (29). These findings may indicate active migration of cells 
from the epithelium through the Rbm, and they may possess proteolytic capacity, acquiring a 
fibroblast phenotype. The transition of epithelium to fibroblastic phenotype is said to be 
driven by TGFβ1 (160). Therefore, the immunostaining of pSmad2/3 as mediators can reveal 
the TGFβ pathway possibly active. However, the results did not show significant difference 
for pSmad2/3 immunostaining for Rbm cells in current-smokers with COPD from non-
smokers, but COPD ex-smokers did. This may indicate that even after quitting smoking, the 
pathogenesis of TGFβ pathway may work as a post-smoking effect. It may be also possible 
that the cells are initiating repairs and TGFβ can also function to induce this repair, as TGFβ 
is involved in normal physiological processes (132). Also, it would be worth looking at 
whether this repair process is occurring only in the Rbm and if it is, why only in this sub-
epithelial layer and not in other areas. Cellularity is not the only change that is seen in the 
Rbm; changes in vascularity have also been noted in COPD patients (118, 137). 
The current study showed that the current-smokers with COPD had a significant increase in 
pSmad2/3 immunostaining in the Rbm blood vessels from non-smokers, however, neither ex-
smokers with COPD nor smokers with normal lung function were significantly different from 
non-smokers. Previous study has shown angiogenesis is hyperactive in the Rbm during 
airway remodelling in smokers with COPD, and TGFβ staining showed increased vessel-
related upregulation in the blood vessels in the Rbm, supporting the active angiogenesis in 
the Rbm possibly through TGFβ pathway (65, 118). A number of studies have shown that 
TGFβ has angiogenic activities (161-163). An in vivo study showed that TGFβ can induce 
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angiogenesis (164). pSmad2/3 as a marker of the TGFβ pathway was increased in the blood 
vessels in this study, indicating the possibility of TGFβ acting through pSmad2/3 signaling in 
COPD current-smokers group. This pathological change may be reversible with smoking 
cessation, as the COPD ex-smokers group was not different from non-smokers group. Also, 
smoking alone may not cause pathogenesis, only when it is combined with the disease 
angiogenesis occurs.. Rbm is not the only sub-epithelial layer where vascular remodelling is 
seen in COPD patients; bronchial vascular remodelling is also seen in the lamina propria (LP) 
(61, 65, 137). 
The current study found increased pSmad2/3 immunostaining in the blood vessels in LP in 
COPD groups compared to non-smokers. This complements previous work by Zanini et al 
who showed that TGFβ staining correlated significantly with vascular area. Calabrese et al 
reported more blood vessels in the LP of smokers and stated angiogenesis is a part of airway 
remodelling in smokers with COPD (165). This is contradicted by a study by Soltani et al 
which stated that the density of vessels in the LP was significantly lower than non-smokers 
(65). Zanini et al also showed larger vascular area in ex-smokers with moderate to severe 
COPD compared to control, but the number of vessels was not different between groups 
(137). These findings suggest that TGFβ is possibly acting through pSmad2/3 in the LP of 
COPD patients. Smoking cessation may cause reversible changes in angiogenesis in the Rbm, 
but not in LP. The increased activity of TGFβ pathway in the endothelial cells of the airways 
may be linked to increased Smad2/3 phosphorylation (60, 78, 166). The use of inhaled 
corticosteroids (ICS) is common in patients with COPD and therefore it is useful to evaluate 
whether the bronchial vascularity in patients with COPD is affected by the use of ICS.  
ICS are widely used among a large proportion of COPD patients (167). The current study 
revealed that ICS did not change the pSmad2/3 immunostaining on blood vessels in COPD 
airways. Studies have shown effectiveness of ICS on airways remodelling in asthma, 
reducing thickness of Rbm and vessels in the mucosa in asthma (147, 148), but only a few 
studies have evaluated the role of ICS in COPD patients. Zanini et al showed that COPD 
patients treated with steroids had reduced vascular area and vessel size, but no effect on 
vessel numbers (137). Similarly, Soltani et al showed that ICS did not change the number of 
vessels in the airway mucosa (65). Zanini et al also showed TGFβ positive cells correlated 
significantly with vascular area and was less in people who were on ICS (137). However, the 
current study found no effect of ICS on Smad2/3 phosphorylation.  It may be due to that 
inflammation is mostly treated with the anti-inflammatory effects of ICS; therefore it is more 
effective in asthma. Smoking, fibrosis and airway remodelling are major contributors to the 
aetiology of COPD in addition to inflammation. It has been suggested that COPD is 
‘resistant’ to ICS (168). There are some studies that did not find any effects with ICS on 
clinical manifestations and airway inflammatory changes in COPD (167, 169). However, 
improvements in clinical symptoms, in quality of life, reduction of acute exacerbations, 
stabilisations of lung function have been reported in many studies (170-172). A potential 
limitation to this study that needs to be addressed is the small number of subjects in placebo 
groups. Therefore, further studies sampling more subjects are needed to clarify this further.      
 
60 
 
4.4 Future direction 
 
TGFβ has been shown to mediate its effect by serine/threonine kinase activity (173), but it 
may also signal through other kinases. Study has shown integration of TGFβ and mitogen-
activated protein kinase (MAPK) induces Smad phosphorylation (174). Also, it has been 
shown that TGFβ receptor activated extracellular signal regulated kinase (ERK) pathway, and 
resulted in increased Smad2 and Smad3 phosphorylation (175). TGFβ acts through multiple 
pathways, rather than one discrete pathway, and further studies of these pathways in COPD 
airways need to be conducted. Furthermore, future studies on pSmad2/3 immunostaining 
should measure total Smad2/3 proteins in order to analyse the ratio of pSmad2/3 to total 
Smad2/3 and the extent to which the proportion of pSmad2/3 immunostaining contributes to 
COPD airways. Additionally, some measures, such as measuring the Rbm thickness, total 
cellularity and vascularity in Rbm and LP may also indicate the proportion to which Smad2/3 
are phosphorylated and their involvements. An interdisciplinary approach combining cellular, 
molecular and immunohistochemistry approaches is required to understand the precise role of 
phosphorylation of Smad2/3 in COPD airways and how it is possibly related to COPD 
pathogenesis.  
  
4.5 Summary 
 
In conclusion, my data suggest that TGFβ is possibly acting through pSmad2/3 signaling to 
induce changes in the epithelium, Rbm morphology, cellularity, and blood vessels in Rbm 
and LP in COPD airways, particularly in those who are smokers. In this regard, the 
epithelium and Rbm may be of particular pathological relevance in smokers and COPD, with 
the Rbm fragmentation, changes in vascularity, and migrating and transitioning epithelial 
cells through Rbm. TGFβ have been implicated in EMT in other situations, but there has been 
little specific work in the airways of smokers and COPD. Further studies are urgently 
required. Focusing on the profile of EMT-related transcription factors such as Smads will be 
a good way of distinguishing the likely active drivers such as TGFβ that act as intermediaries 
between the insult of cigarette smoke on the airway epithelium and downstream events which 
end with clinical phenotypes. Especially, the role of angiogenesis and possible EMT in 
smoking and/or COPD pathogenesis needs more research. 
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Appendix 1: The epithelial cells raw data.  
NC Number of 
Smad cells 
Std Total number 
of cells  
Std Rbm length 
(μm) 
Std 
1 48.2 10.35 52.8 11.08 588.95 80.91 
2 167 83.12 185 90.35 652.53 207.02 
3 92.4 55.21 97.8 56.53 503.97 264.35 
4 183.4 90.28 204.4 87.28 502.11 166.88 
5 32 9.59 61.6 25.38 528.05 101.39 
6 103.6 33.71 141.6 54.61 556.91 102.99 
7 81.6 33.58 94 37.21 485.80 121.04 
8 120.4 42.44 126.2 44.01 470.37 77.09 
9 99 15.60 119.4 18.20 616.81 201.27 
10 57.2 11.97 62.6 14.24 467.75 132.19 
11 105.4 43.46 116.2 54.13 479.24 150.51 
12 107.2 58.17 115.8 58.60 604.62 249.98 
Mean 99.78 (32-183) 40.62 114.78 (53-204) 45.97 538.09 (468-653) 154.63 
       
NLFS Number of 
Smad cells 
Std Total number 
of cells  
Std Rbm length 
(μm) 
Std 
1 62.2 27.23 63.2 27.82 325.56 31.96 
2 63.2 14.92 66 15.25 376.54 64.54 
3 26 19.20 29.2 20.13 319.39 167.18 
4 30.8 10.92 34.2 11.56 458.82 125.28 
5 74.6 39.88 85.2 46.53 387.01 45.57 
6 87.6 18.26 91.8 16.90 415.04 132.98 
7 48.4 39.64 70.6 40.06 414.60 156.27 
8 99.6 33.05 103.2 36.62 397.59 55.39 
9 86.6 44.67 91.4 46.57 394.38 94.37 
10 24.8 12.56 25.2 12.28 415.17 64.56 
11 185.2 64.05 195 63.05 438.34 67.99 
12 103.6 23.14 106.4 24.57 342.31 85.34 
13 155.8 30.27 162.6 37.20 444.45 92.90 
Mean 80.65 (25-185) 29.06 86.46 (25-195) 30.66 394.55 (319-459) 91.10 
       
COPD 
CS 
Number of 
Smad cells 
Std Total number 
of cells  
Std Rbm length 
(μm) 
Std 
1 233.2 79.42 235.2 80.24 582.25 130.05 
2 106.8 53.43 108 53.76 346.48 53.75 
3 32 14.95 34.2 15.69 366.47 131.49 
4 150.4 69.42 154 70.20 592.49 200.08 
5 30.6 8.32 46 19.77 446.54 134.27 
6 133.4 42.78 143 50.26 554.68 81.90 
7 116.4 39.37 117 39.04 453.53 104.89 
8 42.6 7.33 45.4 8.02 372.15 39.13 
9 98.4 61.74 99.6 61.44 405.50 98.45 
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10 97.8 46.85 98.4 46.92 675.43 197.89 
11 71.8 19.54 79 16.78 626.96 116.04 
12 115.4 67.76 116.4 67.15 432.76 78.90 
13 45.2 25.47 46.4 25.91 355.70 63.31 
14 38 12.51 38 12.51 398.55 119.73 
15 18.4 6.91 19.2 6.94 327.99 113.49 
Mean 88.69 (18-233) 37.05 91.99 (19-235) 38.31 462.50 (328-675) 110.89 
       
COPD 
ES 
Number of 
Smad cells 
Std Total number 
of cells  
Std Rbm length 
(μm) 
Std 
1 131.4 25.43 137 31.18 441.91 139.45 
2 72.6 15.37 74.4 14.60 465.83 78.79 
3 41.8 16.44 42.2 16.24 388.75 100.46 
4 140.4 25.09 141.6 25.04 500.17 159.26 
5 81.8 48.44 83.6 50.47 425.76 140.67 
6 70.6 18.76 71.4 18.32 377.95 89.52 
7 69.4 19.03 70 19.66 423.14 72.87 
8 175 27.82 198 33.40 500.71 133.06 
9 72.8 14.04 73.4 14.12 430.80 65.57 
10 88.4 15.73 90 15.22 557.95 164.65 
11 106.4 92.65 110.8 95.01 419.73 142.36 
12 82.6 31.51 83.2 31.22 416.08 66.55 
Mean  94.43 (42-175) 29.19 97.97 (42-198) 30.37 445.73 (378-558) 112.77 
       
 
 
